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Obesity is characterized by chronic, low-grade inflammation that leads to insulin 
resistance and metabolic syndrome. It is well accepted that the expansion of adipose 
tissue leads to a state of relative hypoxia that is associated with inflammation and 
adipocyte dysfunction. While numerous studies have established hypoxia-inducible 
factor-1α (HIF-1α) as a critical transcription factor for metabolic adaptation during low 
oxygen conditions, less is known about the regulation and functionality of HIF-1α 
induced by inflammation under normoxic conditions. Data presented in this dissertation 
demonstrated that HIF-1α is induced by the inflammatory cytokine Oncostatin M (OSM) 
in 3T3-L1 adipocytes during normoxia. The induction of HIF-1α by OSM was regulated 
at the level of transcription and dependent on ERK and AKT signaling pathways. 
Furthermore, data show that HIF-1α was responsible for metabolic and vasculature 
adaptations, such as increased glycolytic gene expression, glucose uptake, lactate 
production and angiogenic gene expression induced by OSM. We further demonstrated 
that OSM contributes to adipose tissue remodeling by reducing cell growth and inhibiting 
adipogenesis. Specifically, OSM inhibited differentiation during mitotic clonal expansion 
(MCE) and prevented the induction of peroxisome proliferator-activated receptor γ 
(PPARγ), CCAAT/enhancer-binding protein α (C/EBPα), adipocyte protein 2 (aP2) and 
adiponectin (ADPN). As MCE is characterized by several rounds of cell cycle, 
examination of cyclins revealed that OSM dramatically reduced cyclin D1. Furthermore, 
HIF-1α knockdown partially restored PPARγ, C/EBPα, aP2 and cyclin D1, suggesting 
that HIF-1α is a mediator of the inhibition of cell growth and differentiation by OSM. Data 
 
also show that the addition of hypoxia-mimetic, CoCl2 and OSM led to a synergistic 
effect on HIF-1α, which suggests that the hypoxia and inflammation implicated during 
obesity may magnify the effect on downstream targets of HIF-1α. These data 
demonstrate an essential role for HIF-1α in the effect of OSM on adaptations in 
adipocytes during normoxia. Collectively, the findings presented here provide insight into 
the molecular mechanisms by which hypoxia and inflammation contribute to metabolic 
adaptation and adipose tissue remodeling. 
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Significance of Research 
 
According to the World Health Organization (WHO), the prevalence of obesity 
worldwide tripled between 1975 and 2016 and over 340 million of these individuals 
classified as overweight or obese were children and adolescents. This ever-expanding 
obesity epidemic is a serious public health concern due to the obesity-related 
complications such as cardiovascular disease, diabetes, and cancer, as well as the 
increased health care costs associated with these diseases. Although organizations 
such as WHO and the Centers for Disease Control and Prevention (CDC) have initiated 
projects and funding that aim to reduce obesity, the prevalence of obesity and diabetes 
remains alarmingly high, signifying the need for improved therapeutic strategies that 
target these obesity-related diseases. It is well established that obesity is associated 
with chronic, low-grade inflammation, which is directly linked to insulin resistance and 
metabolic syndrome. Furthermore, it has been determined that a link between 
inflammation and low oxygen tension exists and contributes to adipocyte dysfunction. 
Overwhelming evidence suggests that the expansion of adipose tissue leads to a state 
of a hypoxia, or low oxygen tension, and that the effects are mediated through hypoxia-
inducible factor-1α (HIF-1α). Although numerous studies have investigated the 
relationship between inflammation and hypoxia, the regulation and effects of HIF-1α 
induced by inflammatory cytokines remain largely unknown. Collectively, the proposed 
research is significant, as it advances our understanding of the regulation of HIF-1α by
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inflammatory cytokines and establishes a functional role for HIF-1α in adipocyte 
dysfunction, which could lead to the creation of new therapeutic targets for improving the 
deleterious effects of hypoxia and inflammation implicated in obesity. 
 
Review of Literature 
 
Obesity. Before the 20th century, humans in both developed and 
underdeveloped countries struggled with poverty, food scarcity and malnutrition as a 
result of low economic productivity and development. A major concern continued to be 
the number of underweight individuals, as this affected both work efficiency and survival. 
However, as countries became more industrialized, the number of adults with excess 
weight began to outnumber those who were underweight (1). In fact, increasing 
industrialization radically transformed the food system, allowing for an increase of 
processed food, which is commonly energy dense and highly refined (2). This change in 
the food system has proven to be a critical turning point and major driver of the global 
obesity epidemic (2,3). 
Obesity is characterized by the expansion of adipose tissue and is most 
commonly defined by body mass index (BMI). A BMI measurement between 25-30 
kg/m2 is considered overweight, while BMI over 30 kg/m2 is classified as obese (1). In 
2014, 36.5% of U.S. adults and 17% of U.S. youth were classified as obese (4). In 2013, 
the prevalence of obese adults was 31% and the prevalence of overweight or obese was 
65% in developed countries. In developing countries, the prevalence of obesity was 
lower, at about 11%, but had similar trends in overweight and obesity as compared to 
developed countries. Between 1980-2013, the prevalence of overweight and obesity 
worldwide increased by 28% for adults and 47% for children (5).  
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This global rise in obesity has major health consequences. Among the many 
complications that arise from obesity including liver disease, cancer, and 
neurodegeneration, perhaps the most concerning is metabolic syndrome (3,6). Metabolic 
syndrome is defined as a conglomeration of factors, such as insulin resistance, chronic 
low-grade inflammation and dyslipidemia that all directly increase the risk of 
cardiovascular disease and type 2 diabetes (7). According to the CDC, in 2015, the 
prevalence of diabetes in the U.S. population of individuals’ ages 18 or older was 12.2%, 
or 30.2 million adults. Of these adults, 7.2 million were unaware or did not report that 
they had the disease. Historically, children with diabetes were diagnosed with type 1 
diabetes. However, with the increase in childhood obesity, the CDC reported that in 
2015, the annual increase for type 2 diabetes in children within the U.S. was 4.8%, and 
from 2011-2012 5,300 children were newly diagnosed with this disease (8). Furthermore, 
according to the International Diabetes Federation, 415 million people worldwide were 
affected by diabetes and it is predicted to rise to 642 million by 2040 (9). The health care 
costs associated with obesity related complications in the U.S. alone are almost $2,000 
per year for each obese individual, which amounts to $150 billion annually (10). 
  These statistics demonstrate that obesity and its related complications have 
severe health and financial consequences for the U.S. and the world at large. Due to the 
many factors that contribute to obesity, finding ways to prevent, reverse, and manage 
obesity related diseases, is critical for the health of future generations. Increased 
research and understanding of cellular mechanisms of adipocyte dysfunction implicated 
during obesity could lead to the improvement of the effects of obesity-related disorders.  
 Adipose Tissue. Adipose tissue is a complex organ composed of a variety of 
cell types and is located throughout the body (11,12). While the primary cell type of 
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adipose tissue is the adipocyte, including preadipocytes and adipocytes, adipose tissue 
is also comprised of macrophages, fibroblasts, lymphocytes, and endothelial cells (13–
15). Adipose tissue has a remarkable capacity for expansion, which allows for energy 
storage and mobilization under fasting or starvation conditions (11,16). This is a 
particularly fascinating evolutionary feature as it has allowed humans to survive in 
severe food shortages and times of uncertainty (17). It also serves as thermal insulation 
for the body and as cushion for organ protection (15).  
 While adipose tissue was once considered to function mainly as a storage depot 
for triglycerides, we now understand that it is a highly active metabolic organ, able to 
secrete a variety of bioactive compounds such as adipokines that play a critical role in 
energy homeostasis, as well as vasculogenesis and immunity (11–14). It was in the 
early 50’s that this view of adipose tissue as merely storage began to shift when G.C. 
Kennedy came up with what became known as the lipostatic hypothesis. Kennedy 
proposed that the adipose tissue had a feedback signal to regulate energy expenditure 
and food intake (18). This hypothesis became heavily explored and confirmed. In 1973 
researchers found that genetically obese mice were unable to produce a sufficient 
satiety factor to regulate food consumption; diabetic mice were able to produce the 
satiety factor but could not respond to it (19).  
Finally, in 1994, the obese gene was identified and sequenced, which allowed 
the lipostatic signal derived from this gene to become known as leptin (20). The 
discovery of leptin was of great significance not only for its ability to regulate body fat, 
but because this showed that adipose tissue is an endocrine organ and that there is a 
physiologic system that regulates metabolism. This new recognition of adipose tissue as 
an endocrine organ led to the discovery of many proteins and factors that are secreted 
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from adipose tissue, termed adipokines (21). It is now widely accepted that adipose 
tissue is a dynamic organ, critical for health and disease and plays huge roles in 
metabolic regulation, obesity, inflammation and insulin resistance. Overnutrition leads to 
obese adipose tissue and dysregulated adipokine secretion, which contributes to 
obesity-related diseases such as diabetes, hyperlipidemia and hypertension (22). 
 Adipose Tissue Dysfunction. As individuals gain weight, adipocytes within the 
tissue increase in number (hyperplasia) and size (hypertrophy). These mechanisms, 
along with infiltration of macrophages, fibrosis and reduced extracellular matrix flexibility 
encompass the term adipose tissue remodeling (23,24). Hypertrophy is considered the 
most critical mechanism for obese adipose tissue (25). It is this expansion of adipocytes 
that leads to decreased insulin sensitivity, reduced adiponectin secretion and increased 
pro-inflammatory cytokines and hypoxia (25,26). Enlarged adipocyte size is associated 
with type 2 diabetes (27). Several mechanisms for this correlation include impaired 
differentiation, increased release of free fatty acids (FFAs), increased secretion of 
cytokines and a reduction in adiponectin, which typically functions to increase insulin 
sensitivity (27,28). 
It is now well established that obesity is associated with chronic, low-grade 
inflammation. It is this state of inflammation that is accompanied by increased secretion 
of pro-inflammatory and pro-atherogenic cytokines, which characterizes the term 
adipocyte dysfunction (28). These cytokines contribute greatly to insulin resistance and 
type 2 diabetes.  For example, tumor necrosis factor alpha (TNF-α) increases lipolysis, 
which promotes the release of fatty acids into circulation and leads to insulin resistance 
in the skeletal muscle and liver (29,30). Adipocyte hypertrophy is also associated with an 
increased number of macrophages, which contributes to the pro-inflammatory phenotype 
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of obese adipose tissue (25). In short, adipose tissue expansion and adipocyte 
hypertrophy, such as found in obesity, is associated with increased inflammation, 
impaired adipogenesis, dysregulated glucose and lipid metabolism, altered adipokine 
secretion and hypoxia (25,31). 
 Hypoxia in Adipose Tissue, HIF-1α . Oxygen is an essential requirement for all 
aerobic organisms. While not typically considered a major macronutrient, oxygen is 
required for respiration and other key metabolic processes. For example, the conversion 
of fatty acids and glucose to ATP via oxidative phosphorylation requires an ample supply 
of oxygen (32). The general level of tissue oxygenation in humans is between 40 and 50 
mmHg (33). However, as illustrated in Fig. 1.1, as adipose tissue expands, the amount 
of oxygen to the tissue decreases, causing a state of hypoxia, or low oxygen tension 
(33,34). In fact, during obesity, the postprandial adipose tissue blood flow response is 
attenuated and the underlying mechanism is associated with insulin sensitivity (35,36). 
In mammals, cells sense this low extracellular oxygen tension and evolutionarily 
responses are activated.  
Hypoxia, such as implicated in obesity, leads to adipose tissue dysfunction by 
causing several functional changes. First, it causes a switch from oxidative metabolism 
to anaerobic metabolism by inhibiting the expression of genes associated with oxidation 
and increasing glycolytic gene expression (Fig.1.2) (37,38). This metabolic adaptation 
causes increased glucose uptake and lactate production (39). Additionally, one 
proposed underlying mechanism for the inflammation found in obesity is hypoxia. 
Hypoxia causes an increase in several inflammatory adipokines such as interleukin-6 
(IL-6), vascular endothelial growth factor (VEGF), plasminogen activator inhibitor 1 (PAI-
1) and causes a reduction in anti-inflammatory molecules such as adiponectin (39,40). 
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Other effects of hypoxia that contribute to adipocyte dysfunction include modulation of 
lipid metabolism and reduced insulin sensitivity (41). 
The primary transcriptional signals in response to hypoxia are the members of 
the HIF family (33,42). The three main hypoxia-inducible factors (HIFS) are HIF-1, HIF-2, 
and HIF-3. While the role of HIF-3 in hypoxia is much less understood than HIF-1 and 
HIF-2, it is HIF-1 that has become known as the ‘master regulator of oxygen 
homeostasis’ (33,43,44). HIF-1 is a heterodimeric complex composed of HIF-1α and 
HIF-1β, also known as aryl hydrocarbon nuclear translocator (ARNT), that is present in 
all metazoan species (45,46). Although HIF-1β is constitutively expressed, HIF-1α has a 
very short half-life and is continually synthesized and degraded under normoxia 
(33,42,44). Within the HIF-1α subunit, there are three hydroxylation sites; two prolyl 
residues in the oxygen-dependent degradation domain (ODDD) and one asparaginyl 
residue in the C-terminal transactivation domain (C-TAD). In well-oxygenated 
environments, Fe (II), oxygen and prolyl hydroxylase domain-containing enzymes 
(PHDs) catalyze prolyl hydroxylation. Proline residue hydroxylation allows HIF-1α to be 
recognized and targeted for degradation by von Hippel-Lindau protein (pVHL), which 
leads to ubiquitination and proteasomeal degradation (33,47). In the absence of oxygen, 
during hypoxic stress, PHD activity is inhibited, the pVHL cannot bind and HIF-1α 
becomes stabilized. HIF-1α then translocates to the nucleus, heterodimerizes with HIF-
1β and allows for transcription of target genes by binding to hypoxia-response elements 
(HREs) in the regulatory regions of these genes (44,46).  
 While there are several mechanisms by which hypoxia induces molecular and 
cellular responses, many of the hypoxic effects are mediated specifically through HIF-
1α. This allows researchers to study HIF-1α dependent genes under normoxic 
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conditions by using chemical hypoxia mimetics such as CoCl2, which inhibits PHD 
activity and thereby stabilizes the protein. HIF-1α transcriptionally regulates many 
different genes that encode for proteins involved in a variety of processes such as 
angiogenesis, inflammation, cellular proliferation/survival and glucose metabolism 
(33,48,49).  
Hypoxia, Oxidative Metabolism, Glucose Utilization and Lactate Production. 
The primary mechanism for creating an adequate supply of cellular ATP is mitochondrial 
respiration. This process is dependent on oxygen as the final electron acceptor in the 
electron transport chain (ETC). The transfer of electrons through the various ETC 
complexes creates a gradient that drives the synthesis of ATP. If too little oxygen is 
present, the flow of electrons is halted, leading to a reduced oxidative metabolism and 
increased production of reactive oxygen species (ROS) (50). As illustrated in Fig.1.2, a 
critical metabolic adaptation to hypoxia is the stabilization of HIF-1α, which causes a 
switch from oxidative to glycolytic metabolism (33,44,45). HIF-1α is able to maintain ATP 
production through increased anaerobic metabolism and reduce uncontrolled toxic ROS 
generated by the ETC (44).  
Pyruvate dehydrogenase kinase 1 (PDK1) phosphorylates pyruvate 
dehydrogenase (PDH), which inactivates the complex that converts pyruvate to acetyl-
CoA for entry into the TCA cycle. During hypoxia, HIF-1α stimulates PDK1 activity, 
resulting in a decreased flux through the TCA cycle and inhibition of oxidative 
phosphorylation (51). In fact, under hypoxic conditions, HIF-1α null mouse embryo 
fibroblasts (MEFs) fail to activate PDK1, leading to increased ROS and apoptosis. 
Additionally, HIF-1α regulates cytochrome c oxidase 4 (COX4) in the ETC by activating 
COX4-2, which optimizes the efficiency of respiration during hypoxia (52). These HIF-1α 
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dependent adaptations are important for the prevention of toxic ROS and conservation 
of ATP (44,51). 
Reduced oxidative phosphorylation during hypoxia causes a shift towards 
anaerobic metabolism through increasing glucose transporters and enhancing glycolytic 
rates, which results in an increase in lactate production (48,53,54). The glucose uptake 
process is regulated by glucose transporters. Adipocytes express glucose transporters 
from each class of the GLUT family (55). However, it is GLUT1 that is the main 
transporter for basal glucose uptake. In response to hypoxia in human adipocytes, 
GLUT1, GLUT3 and GLUT5 gene expression is increased, as well as 2-deoxy-D-
glucose uptake (53,56). Additionally, HIF-1α is specifically involved in the increases in 
GLUT1 and glucose uptake (40,57). In order for cells to further adapt to oxygen 
restrictions, hypoxia also leads to increased glycogen accumulation in a HIF-1α 
dependent manner (58–60). In several cell types, this increase in glycogen storage by 
HIF-1α is mediated through glycogen synthase 1 (GYS1) (60). Additionally, in 
adipocytes and other cell types, hypoxia causes an up-regulation of genes that encode 
for enzymes in the glycolytic pathway (38,54,61). The glycolytic genes up-regulated by 
hypoxia include hexokinase 1 and 2 (HK1 and HK2), glucose-6 phosphate isomerase 
(G6PI), phosphofructokinase (PFK), aldolase A and C (ALDOA and ALDOC) , 
triosephosphate isomerase (TPI), phosphoglyceratekinase 1 (PGK1), enolase 1 and 2 
(ENO1 and ENO 2) and lactate dehydrogenase (LDHA) (38,54,62). Not only are these 
key glycolytic enzymes up-regulated by hypoxia, they are dependent on HIF-1α (62). 
The end product of the glycolytic pathway is pyruvate. In the presence of oxygen, 
pyruvate is converted into acetyl-CoA for entry into the TCA cycle for the production of 
NADH and FADH2 for oxidative phosphorylation. Under anaerobic conditions, pyruvate is 
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converted into lactate and transported out of cells by monocarboxylate transporters 
(MCTs). During conditions of hypoxia, adipocytes have increased release of lactate, as 
well as increased gene expression of MCT1 and MCT4 (39,63). In both adipocytes and 
tumor cells, MCT4 is directly mediated by HIF-1α (64,65). In fact, the amount of glucose 
converted to lactate directly correlates with fat cell size, congruent with hypoxia 
increasing as adipose tissue expands (33). One effect of the export of lactate from the 
cell into the extracellular environment is an increase in the inflammatory response in 
macrophages, which provides one mechanism by which hypoxia and inflammation are 
associated (66).  
Hypoxia and Inflammation. Obesity can be characterized by chronic, low-grade 
inflammation with increased circulating levels of inflammatory molecules (25). These 
inflammatory markers correlate with hypertrophic adipocytes, which are strongly 
associated with cardiometabolic risk (31). It is also this expansion of adipocytes that 
leads to hypoxia. In 2004, it was proposed that hypoxia initiates the inflammatory 
response in adipose tissue by directly dysregulating adipokine production (37). To 
investigate the link between hypoxia and inflammation, studies have examined the effect 
of low oxygen conditions and hypoxia mimetics on adipokine production. In human 
adipocytes, exposure to varying degrees of oxygen causes a dose-dependent increase 
in adipokine production. It has been shown that at 1% oxygen, there is a nine-fold 
increase in mRNA for leptin, 27-fold increase for VEGF, 22-fold increase in fasting-
induced adipose factor (Angplt4/FIAF), 7.2-fold increase for IL-6 and a 6.6-fold increase 
for PAI-1. Additionally, anti-inflammatory adipokine, adiponectin is reduced by 3-fold 
under hypoxic conditions. The alterations in these mRNA levels are accompanied by an 
increase in the release of adipokines from the adipocytes. As oxygen levels decrease, 
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the secretion of leptin, VEGF, IL-6 and PAI significantly increase, while adiponectin 
secretion decreases (39) Moreover, the changes in adipokine expression and secretion 
by low oxygen conditions correspond to levels of HIF-1α and exposure to hypoxia 
mimetic, CoCl2 (40). Exposure to CoCl2 in murine adipocytes increases the level of 
protein of pro-angiogenic factors VEGF, leptin and matrix metalloproteinases, MMP-2 
and MMP-9 (63). Many of these hypoxia-sensitive genes are dependent on the induction 
of HIF-1α (37). 
It has been proposed that the increase of circulating adipokines in response to 
hypoxia is to stimulate angiogenesis and increase blood flow to the tissue (Fig.1.2). 
Angiogenesis is critical for the function of adipose tissue and underlies the process by 
which new blood vessels expand from existing vasculature. A major aspect of 
angiogenesis is the proliferation of endothelial cells, which is primarily regulated by 
VEGF-A, the master regulator of endothelial cell growth. In response to increased HIF-
1α during hypoxic conditions in adipose tissue, increased VEGF transcription stimulates 
angiogenesis (67). In mice models, it has been shown that overexpression of VEGF 
improves the insulin resistance induced by a high fat diet (HFD). On the other hand, 
ablation of VEGF in adipose tissue increases inflammation and reduces glucose 
tolerance and insulin sensitivity (68). These studies confirm a link between hypoxia and 
inflammation, as well as a role for HIF-1α induced VEGF for adaptation to adipocyte 
hypertrophy and insulin resistance (Fig.1.2). 
Inflammation and Cytokine Secretion. Chronic, low-grade inflammation found 
during obesity is associated with metabolic syndrome and an increased risk for type 2 
diabetes and cardiovascular disease. Obesity-induced inflammation affects several 
organs within the body including adipose, pancreas, liver, muscle, heart and brain (6,25). 
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Since inflammation of adipose tissue is considered a hallmark of obesity and plays an 
important role in the development of insulin resistance, current hypotheses support the 
idea that adipose inflammation is the basis for metabolic syndrome (69). Both clinical 
and epidemiological studies have confirmed this connection. In 1995, Speigelman’s 
group was the first to show that obese individuals have an increased expression and 
production of the cytokine TNF-α in adipose tissue and that it is positively correlated with 
insulin resistance (70). A reduction in body weight is associated with a decrease in TNF-
α expression (71). Higher BMI, which is seen in those who have excess adipose tissue, 
causes an increase in C-reactive protein (CRP) concentrations (72). IL-6 induces CRP 
and both are associated with the development of type 2 diabetes (73). On the other 
hand, anti-inflammatory molecule adiponectin, which helps protect against metabolic 
syndrome, is decreased during obesity (74). These findings suggest that the balance 
between pro-inflammatory and anti-inflammatory adipokines is critical for normal 
metabolic function.  
Adipose tissue in obese individuals has increased accumulation of immune cells, 
such as macrophages. Infiltration of macrophages within the adipose tissue is critical for 
the production of pro-inflammatory cytokines and is linked to insulin resistance (75). 
During obesity, there is an enrichment of macrophages and T lymphocytes, which cause 
a switch from M2 macrophage polarization to M1 macrophage polarization. Whereas M2 
polarization maintains a healthy, anti-inflammatory state within the adipose tissue, M1 
polarization leads to the secretion of pro-inflammatory cytokines such as TNFα, IL-6 and 
IL-β (76). These macrophage-secreted factors promote systemic inflammation and 
impair the ability of adipocytes to differentiate, which leads to insulin resistance (77).  
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Macrophage infiltration also increases the production of reactive oxygen species 
(ROS) and oxidative stress (69). ROS cause damage to cellular proteins, lipids and 
nucleic acids, as well contribute to the initiation of insulin resistance (78). Importantly, 
the pro-inflammatory cytokines produced from macrophage infiltration leads to 
mitochondrial dysfunction (69). For example, increased TNF-α causes significant 
changes in mitochondrial metabolism. Prolonged treatment of cultured adipocytes with 
TNF-α causes an increase in basal respiration and proton leak but a decrease in 
respiratory capacity. These changes occur in conjunction with an increase in 
extracellular acidification rate (ECAR), which measures the cell’s dependence on 
anaerobic glycolysis (69). TNF-α and several other inflammatory markers, such as IL-6 
and IL-1β, cause a dose-dependent increase in GLUT1 and GLUT3 mRNA, which is 
accompanied by an increase in glucose uptake (79). Additionally, TNF-α increases the 
production of ROS, which directly damage the mitochondria by decreasing ATP 
synthesis and dysregulating lipid homeostasis, leading to overall mitochondrial 
dysfunction (80). Collectively, these data demonstrate that increased inflammation and 
adipokine secretion in obesity directly impact mitochondrial metabolism and insulin 
resistance. 
Oncostatin M. One family of cytokines, the IL-6 family, is a group of cytokines 
involved in various biological processes such as inflammation, proliferation, 
differentiation and immune response. The IL-6 family is also referred to as the 
glycoprotein 130 (gp130) family, because these cytokines rely on the gp130 receptor 
complex to mediate signal transduction (81). Recently, gp130 cytokines have been 
studied as potential therapeutic targets in obesity as research has shown that adipocytes 
and adipose tissue are sensitive to their secretion (82). One gp130 cytokine, Oncostatin 
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M (OSM), is unique because it also requires a special receptor, Oncostatin receptor β 
(OSMRβ) to mediate its effects (83,84). In fact, in the murine system, OSM only binds to 
the gp130/OSMRβ complex (85). OSM was originally identified and cloned in 1986 when 
it was found to be a cell growth regulator, having the ability to inhibit proliferation on the 
A375 human melanoma cell line (86).  
The main producers of OSM include monocytes, macrophages, T cells, 
neutrophils and dendritic cells. The production and secretion of OSM leads to the 
activation of several signaling pathways. In fact, out of all IL-6 cytokines, OSM has the 
broadest signaling profile (85). This cytokine activates the JAK/STAT pathway, the 
mitogen-activated protein kinases (MAPK) ERK1/ERK2, the stress activated protein 
kinases p38 and c-Jun N-terminal pathway and protein kinase C delta (PKCδ) pathway 
(83,85). The activation of these signaling pathways by OSM leads to downstream effects 
in a variety of tissues and targets such as the liver, bone marrow, central/peripheral 
nervous system, muscle, heart, cancer and adipose tissue (84,85,87). Within the liver, 
OSM affects regeneration, differentiation and lipid metabolism (85). For example, OSM 
increases both the number of cell surface low density lipoprotein (LDL) receptors, as well 
as LDL uptake in a hepatoma cell line, which indicates a major role for OSM in 
cholesterol homeostasis within the liver (88). In regards to bone metabolism, several 
gp130 cytokines regulate both osteoblast and osteoclast activity (83). OSM increases 
bone colony numbers during the early proliferation phase of differentiation, but also 
causes an increase in apoptosis (89). Interestingly, the expression level of OSM 
increases throughout the progression of osteoblast differentiation, but OSMRβ 
expression decreases (90). Regulation of bone metabolism by OSM is sensitive to time 
and cell type (83). In skeletal muscle cells, OSM treatment induces growth arrest by 
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inhibiting proliferation, blocking cell cycle progression from G1 to S phase and 
significantly reducing cyclin D1 protein levels (91). These data indicate the ability of 
OSM to cause growth arrest by regulating cell cycle. 
OSM expression is also found in the central nervous system (CNS) originating in 
microglia, astrocytes, neurons and infiltrating leukocytes (83,92). OSM expression levels 
increase and correlate with several types of tumors, human immunodeficiency virus 
associated dementia (HAD), multiple sclerosis (MS) and epileptic seizures (92). 
Importantly, within the CNS, OSM has both pro- and anti-inflammatory actions, 
depending on the microenvironment. In fact, when OSM was first discovered for its’ 
ability to inhibit cancer growth, researchers were examining OSM for anti-inflammatory 
properties for arthritis (83). However, it is the anti-proliferative effect of OSM in cancer 
cells that has been extensively studied over the last decade. OSM not only inhibits 
growth of human melanoma cell lines, it also regulates osteosarcoma proliferation and 
reduces proliferation of breast cancer in several cell lines (93,94). While OSM has a 
seemingly anti-proliferative role in cancer, some research suggests that it has a pro-
tumorigenic role in some cell types (83). Collectively, OSM plays major roles in the 
regulation of a variety of important biological processes resulting in many physiological 
implications, which are dependent upon both species and cell type. 
Oncostatin M in Adipose Tissue and Obesity. As mentioned previously, OSM 
is produced in several cells types such as T-cells and macrophages (85). Since T-cells 
and macrophages can be found in adipose tissue, this means OSM is produced within 
the adipose tissue. Although OSM is not specifically produced by preadipocytes or 
adipocytes, both cell types have OSM receptors, allowing them to be responsive to OSM 
(84). Research has shown that as humans become obese, OSM protein expression in 
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fat tissue increases. Additionally, OSM mRNA levels are increased in subcutaneous 
adipose tissue of obese individuals, compared to lean, and correlate with insulin levels, 
body weight and are inversely correlated with glucose disposal rate (87). Similarly, in 
epididymal adipose tissue from ob/ob mice, both the levels of OSM and OSMRβ are 
increased compared to lean littermates (87). In high fat-fed mice, OSM expression is 
significantly increased in adipose tissue T-cells and OSMRβ expression is increased 
following high fat feeding. OSM receptor knockout mice have increased insulin 
resistance and adipose tissue inflammation (95). These findings indicate that OSM is 
produced from adipose tissue, OSM levels are significantly increased during conditions 
of obesity and that OSM receptor levels are involved in the regulation of obesity. 
 Adipogenesis describes the process of fibroblasts and preadipocytes 
differentiating into mature adipocytes. Adipogenesis involves a cascade of transcription 
factors and changes in gene expression, which first lead to alterations in cell shape and 
ultimately lead to terminal differentiation (96,97). While there are a multitude of factors 
that play a regulatory role during early differentiation, a key underlying mechanism 
involves the quick induction of C/EBPβ and C/EBPδ, which are obligatory to drive 
expression of “master regulators” of adipogenesis, such as PPARγ and C/EBPα (96,98). 
Additionally, PPARγ and C/EBPα cross-regulate each other to drive differentiation (98). 
Terminal differentiation then allows preadipocytes to acquire the characteristics of fully 
mature adipocytes, including an increase in glucose transporters, insulin receptors and 
adipocyte proteins such as leptin and adipsin (96). It is well accepted that OSM inhibits 
adipocyte differentiation (81,84,99–101). In 3T3-L1 preadipocytes, OSM inhibits 
differentiation through the Ras/ERK and STAT5 signaling pathways. OSM exerts its 
effects by impacting the early phase of differentiation and may regulate C/EBPβ activity 
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(100). Additionally, OSM treatment reduces lipid content and the number of differentiated 
adipocytes, indicating a role for OSM in dedifferentiation of adipocytes (102). Inhibiting 
adipogenesis blocks fat cell expansion, which leads to insulin resistance (84). 
 OSM also regulates the expression and secretion of several adipokines. 
Exposure of 3T3-L1 adipocytes to OSM increases the expression of proinflammatory 
cytokines tissue inhibitor of metalloproteinases 1 (TIMP1), monocyte chemoattractant 
protein 1 (MCP1), insulin-like growth factor binding protein 3 (IGFBP3), 
osteopontin/secreted phosphoprotein1 (Spp1) and PAI-1. However, the induction of 
these adipokines was attenuated upon knockdown of OSMRβ, indicating a role for 
OSMRβ signaling in OSM-induced adipokine expression (95). OSM also has the ability 
to decrease adipokines, such as adiponectin. Adiponectin is an anti-inflammatory 
cytokine that is involved in regulating glucose levels and lipid metabolism. In fact, the 
concentration of adiponectin in plasma is decreased in obese and type 2 diabetic 
patients and reduced levels of adiponectin are related to insulin resistance (103). 
Therefore, the OSM-induced reduction of adiponectin is of particular significance.  
 As mentioned, angiogenesis is the process of forming new vasculature to 
continue supplying the expanding and proliferating adipocytes (67). Major regulators of 
angiogenesis include VEGF and to some extent, PAI-1 (67,104). As previously 
described, VEGF mediates the stimulation of endothelial cell proliferation (67,68,105). 
PAI-1, on the other hand, plays an important role in the fibrinolytic system and has also 
been shown to promote endothelial cell migration toward fibronectin, indicating a role for 
PAI-1 in angiogenesis (104,106). While both VEGF and PAI-1 are involved in the 
angiogenic response, VEGF seems to protect against high-fat diet induced obesity, 
improve insulin sensitivity and glucose tolerance, while PAI-1 strongly correlates with 
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BMI and is considered a risk factor for cardiovascular disease (106–109). Nonetheless, 
treatment of adipocytes with OSM increases both mRNA expression and protein 
production of VEGF and PAI-1. In both cases, OSM-induced VEGF and PAI-1 is 
dependent on the JAK/STAT pathway (106,110).  
 OSM and HIF-1α . Research indicates that cytokines and other growth factors 
can induce HIF-1α, the primary protein responsible for the various effects of hypoxia. For 
example, IFN-γ, IL-1β and TNF-α have a stimulatory effect on HIF-1 binding activity 
(111,112). In smooth muscle cells, angiotension II, thrombin and platelet-derived growth 
factor (PDGF) all strongly induce HIF-1α (113). Although hypoxia remains the 
incontestable inducer of HIF-1α, these data indicate that cytokines and growth factors 
have the ability to regulate HIF-1α even in normoxic conditions. Additionally, the 
activation of HIF-1α by these cytokines leads to many of the downstream effects caused 
by hypoxia (111–113). Of particular relevance, research indicates that in hepatic cells, 
OSM leads to the transcriptionally regulated induction of HIF-1α (114). As mentioned, 
OSM activates the JAK/STAT signaling pathway (83,85). It turns out that the induction of 
HIF-1α by OSM in liver cells is dependent on STAT3. Additionally, OSM stimulation 
leads to increased expression and secretion of both VEGF and PAI-1 and these 
increases are dependent on HIF-1α (114). 
 As indicated previously, hypoxia causes a switch from oxidative phosphorylation 
to anaerobic metabolism by increasing the expression of glycolytic genes and regulating 
glucose uptake and lactate production (48,53,54). In a human hepatocyte cell line, OSM 
was able to up-regulate HIF-1α under normoxic conditions and increase pyruvate 
dehydrogenase kinase 1 (PDK1) expression and protein levels (115). This data 
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correlates with other findings that HIF-1α specifically trans-activates the gene encoding 
PDK1 (51). PDK1 inhibits the conversion of pyruvate to acetyl CoA, which reduces 
mitochondrial respiration and subsequently increases the conversion from pyruvate to 
lactate (45). The result of an increase in PDK1 is a reduction in the oxidative TCA cycle 
flux (115). While research has not fully linked OSM to mitochondrial metabolic changes, 
some cytokines do lead to significant changes in mitochondrial bioenergetics. Treatment 
of 3T3-L1 adipocytes with TNF-α, IL-1β and IL-6 all result in changes of respiration 
profiles. These cytokines significantly change basal respiration, proton leak, ATP 
turnover, maximum capacity and basal extracellular acidification rate (ECAR). In 
particular, all cytokines lead to a reduction in maximum capacity and TNF-α significantly 
increases glucose uptake and basal ECAR due to an increase in lactate efflux (69).. 
Mounting evidence indicates that hypoxia causes changes in adipocyte bioenergetics 
and other data reveal that OSM up-regulates HIF-1α and also impacts mitochondrial 
metabolism in some cell types. However, studies to link OSM and HIF-1α to adipocyte 
metabolism remain uninvestigated. 
 For terminal differentiation to occur, cells must go through mitotic clonal 
expansion (MCE), which is characterized by re-entry into cell cycle and several rounds 
of mitosis (96). Cell cycle is a tightly regulated process with four different phases Gap 1 
(G1), synthesis (S), Gap 2 (G2) and mitosis (M) (116). The progression from G1 to S 
phase is a critical step as once cells enter S phase, they are committed to cell division 
(116,117). This transition depends on the E2F family of transcription factors, as well as 
increased cyclin-cyclin dependent kinase (CDK) activity (117). As mentioned, OSM 
inhibits adipocyte differentiation and in some cell types regulates cell cycle progression 
by inhibiting the transition from G1 to S phase (82,84,91). Research also indicates that 
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hypoxia inhibits adipocyte differentiation and this arrest is dependent on HIF-1α (118–
121). Additionally, there is overwhelming evidence that in many cell types, hypoxia 
causes cell cycle arrest that is dependent on HIF-1α (116,122–125). For example, in 
mouse embryonic fibroblasts and splenic B lymphocytes, the deletion of HIF-1α inhibited 
the hypoxia-induced G1 arrest. In this case, the mechanism responsible for a G1 arrest 
is a HIF-1α dependent increase in p27 expression and hypophosphorylation of Rb (124). 
Similarly, in kidney epithelial cells, hypoxia caused cell cycle arrest at G1 phase by 
downregulating CDK2 activity, which correlated with p27 expression and 
hypophosphorylated RB (125). Collectively, it is clear that in many cell types HIF-1α 
regulates cell cycle progression, specifically at the G1/S phase transition (126). 
However, whether OSM-induced HIF-1α alters cell cycle progression during adipocyte 
differentiation is yet to be fully elucidated. 
 Review Summary. Obesity is a global health issue with major health 
consequences such metabolic disease, which encompasses type 2 diabetes and 
cardiovascular disease (3,6). Research indicates that obesity leads to hypertrophy, or 
expansion of adipocytes, within the adipose tissue and that this expansion leads to 
hypoxia, dysregulated adipokine secretion, inflammation and ultimately insulin resistance 
and type 2 diabetes (25,26,28). Evidence suggests that as adipocytes expand, the 
oxygen to adipose tissue doesn’t increase proportionately, leading to a state of hypoxia. 
Ultimately, hypoxia causes functional changes such as a switch from oxidative 
metabolism to anaerobic metabolism and the regulation of cell cycle progression 
(33,34,37,38,126). Many of the effects of hypoxia are mediated through the transcription 
factor HIF-1α, which becomes stabilized in low oxygen conditions and regulates over 
100 different genes (33,49). Interestingly, research has found that cytokine Oncostatin 
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M, which is produced from adipose tissue and increased during obesity, can induce HIF-
1α and cause similar effects as hypoxia (84,87,114). While the relationship between 
OSM and HIF-1α has been established in some cell types, few studies have addressed 
their relationship and downstream effects in adipocytes.  Therefore, we have proposed 
the following study objectives below to address our central hypothesis that OSM 
regulates adipocyte function and differentiation through mechanisms involving HIF-1α.  
 
Study Objectives 
Chapter II. It is well known that hypoxia causes functional changes within the 
adipose tissue during obesity. It is also established that there is a link between 
inflammation and hypoxia. Additionally, research demonstrates that OSM correlates with 
obesity and has the ability to up-regulate HIF-1α. However, the regulation and effects of 
OSM-induced HIF-1α have not been fully examined. Therefore, the objective of the 
study summarized in chapter II is to examine the role of HIF-1α in OSM-induced 
metabolic and angiogenic adaptations. We will determine 1) how HIF-1α is regulated by 
OSM, 2) the effect of OSM on glycolytic metabolism and angiogenic adipokine secretion, 
3) a functional role for HIF-1α in OSM-mediated metabolic adaptations, as proposed by 
our working model (Fig.1.3). 
Chapter III.  Although evidence suggests that OSM affects adipocyte 
differentiation and cell cycle progression, a role for HIF-1α in this OSM-mediated 
process has not been investigated. Therefore, the objective of chapter III is to determine 
the role of OSM and OSM-induced HIF-1α in adipocyte cell growth, differentiation and 
cell cycle progression. We will 1) examine the regulation of preadipocyte growth and 
differentiation by OSM, 2) investigate the effect of OSM on cell cycle regulators, 3) 
 22 
establish the role of HIF-1α in mediating OSM-induced adipose tissue remodeling as 
proposed by our working model (Fig.1.3). 
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Figure 1.1. Oxygen Tension as Adipose Tissue Expands. As adipose tissue 







Figure 1.2. Stabilization of HIF-1α  causes Metabolic Adaptations in Adipocytes. 
Stabilization of HIF-1α by hypoxia regulates the expression of genes involved in 










Figure 1.3. Working Model of the Regulation of HIF-1α  by OSM and Synergistic 
Effects with Hypoxia.  This model illustrates that the expansion of adipose tissue 
during obesity is accompanied with macrophage infiltration, inflammation and hypoxia. It 
predicts that the inflammatory cytokine OSM transcriptionally regulates HIF-1α and that 
the up-regulation of HIF-1α will occur in a synergistic manner with hypoxia and lead to 
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Adipose tissue is a highly dynamic metabolic organ that plays a key role in 
energy homoeostasis. The expansion of adipose tissue results in a state of hypoxia, 
leading to the accumulation of hypoxia-inducible factor-1α (HIF-1α). Evidence suggests 
that hypoxia underlies the link between inflammation and adipocyte dysfunction. Recent 
studies demonstrate a key role for specific inflammatory cytokines in the regulation of 
HIF-1α and downstream effects. This study investigates the regulation of HIF-1α by the 
inflammatory cytokine, Oncostatin M (OSM), as well as a role for HIF-1α in OSM-
mediated effects on glycolytic function and adipokine expression in 3T3-L1 adipocytes. 
Data presented here demonstrate that HIF-1α was induced by OSM at the level of gene 
expression and was dependent on ERK and AKT signaling pathways. Concurrent 
stimulation with hypoxia-mimetic, CoCl2 and OSM caused a synergistic effect on HIF-1α, 
suggesting that during obesity, when both hypoxia and inflammation are present, there 
may be an amplifying effect on downstream targets of HIF-1α. Additionally, OSM 
increased glycolytic gene expression, glucose uptake and lactate production in a HIF-1α 
dependent manner. Finally, we show that OSM induction of angiogenic factors, vascular 
endothelial growth factor (VEGF) and plasminogen activator-1 (PAI-1), was dependent 
on HIF-1α. Collectively, these results suggest that HIF-1α has an essential role in the 
OSM-induced adaptations in adipocyte metabolism and vascularization during normoxia.  
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Introduction 
 Overweight and obesity are multifaceted diseases that are characterized by the 
expansion of adipose tissue and the increased risk of non-communicable diseases such 
as cardiovascular disease, stroke, diabetes and cancer (1,2). Although obesity is 
preventable, 36.5% of U.S. adults and 17% of U.S. youth were classified as obese in 
2014 (3). Research indicates that the development of obesity-related diseases is, in part, 
regulated by white adipose tissue (WAT), which serves not only as an energy reservoir 
but also as a main secretory organ and site of inflammation (4). WAT is a highly 
metabolic organ that plays a critical role in energy homeostasis, obesity, inflammation 
and insulin resistance (5–7). As adipose tissue expands, the amount of oxygen to the 
tissue does not increase proportionally, leading to a state of tissue hypoxia or low 
oxygen tension, which results in various metabolic changes, as well as dysregulated 
adipokine production ((4,8).  
Hypoxia activates the transcription factor, hypoxia-inducible factor-1α (HIF-1α), 
which has been proposed as a link between low oxygen tension and inflammation (8). 
HIF-1α is known as the “master regulator of oxygen homeostasis” (8–10). While HIF-1α 
is continually synthesized and degraded under normoxia, low oxygen conditions allow 
for stabilization by suppressing protein degradation (8,11). Once HIF-1α becomes 
stabilized, it translocates to the nucleus and heterodimerizes with HIF-1β for 
transcription of target genes (10,12). Due to the fact that many of the hypoxic effects are 
mediated through HIF-1α, researchers are able to study the effects of HIF-1α-dependent 
genes under normoxic conditions using chemical hypoxia mimetics, such as CoCl2. HIF-
1α is involved in the transcription of genes that encode for proteins involved in a variety 
of processes (8). Importantly, the induction of HIF-1α is a critical metabolic adaptation to 
 38 
hypoxia due to its role in switching from oxidative to glycolytic metabolism (8,10,13). This 
switch allows for the maintenance of ATP production through increased anaerobic 
metabolism. For instance, during hypoxia, HIF-1α stimulates pyruvate dehydrogenase 
kinase 1 (PDK1), which phosphorylates pyruvate dehydrogenase (PDH), leading to the 
inhibition of the conversion from pyruvate to acetyl-CoA and results in reduced aerobic 
oxidation (14). HIF-1α is also specifically involved in increasing glucose transporter 
GLUT1, as well as glucose uptake in adipocytes (15,16). Additionally, in adipocytes and 
other cell types, hypoxia up-regulates genes that encode for enzymes in the glycolytic 
pathway (17–19). HIF-1α is also responsible for dysregulating adipokine production, 
which correlates with the inflammatory response (15,20,21). 
It is well established that obesity is also associated with chronic, low-grade 
inflammation, which characterizes the term adipocyte dysfunction (22). In fact, adipose 
tissue inflammation may be the underlying basis for metabolic syndrome (23). The 
increase in pro-inflammatory cytokines leads to significant changes in mitochondrial 
metabolism, lipid homeostasis and insulin sensitivity (24,25). Of interest, research has 
shown that the gp130 cytokine, Oncostatin M (OSM), is increased as obesity increases. 
Specifically, OSM correlates with insulin levels, body weight and inversely correlates 
with glucose disposal rate (26). On the other hand, OSM receptor knockout mice have 
increased insulin resistance and adipose tissue inflammation (27). Evidence also 
suggests a role for OSM in the regulation and secretion of several adipokines (27–29).  
More recently, there is growing interest in the link between hypoxia and 
inflammation. Research has shown that some cytokines, such as interferon-γ (IFN-γ), 
interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and OSM have the ability to 
increase HIF-1α, even under normoxic conditions (30,31). Evidence suggests that in 
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some cell types, OSM and other cytokines mediate processes typically regulated by 
hypoxia such as metabolic reprogramming, adipokine production and insulin signaling 
(23,32). For instance, in adipocytes, TNF-α and other cytokines significantly change 
respiration profiles and glucose uptake (23). In human hepatocytes, OSM up-regulates 
HIF-1α and increases PDK1 expression and protein levels, which results in a reduction 
in the oxidative TCA cycle flux (33). OSM stimulation in hepatic cells also leads to 
increased expression and secretion of VEGF and PAI-1 and HIF-1α dependent manner 
(32). 
Although evidence indicates that hypoxia and OSM cause similar outcomes and 
the relationship between HIF-1α and OSM has been established in some cell types, 
relatively little attention has been given to its role in adipocytes. Since OSM has been 
reported to induce HIF-1α, we sought to elucidate the regulatory mechanisms of HIF-1α 
induction and subsequent effects on adipocyte function. We report here that OSM 
transiently induces functional HIF-1α at the level of transcription, rather than through 
protein stability as well known for hypoxia. Additionally, the induction of HIF-1α by OSM 
is dependent on ERK and AKT signaling pathways. Concurrent stimulation with hypoxia-
mimetic, CoCl2 and OSM causes a synergistic effect on HIF-1α, suggesting that during 
obesity, when both hypoxia and inflammation are present, there may be an amplifying 
effect on downstream targets of HIF-1α. Moreover, we observed that OSM increases 
glycolytic gene transcription, glucose uptake and lactate production and that this 
metabolic reprogramming is dependent on HIF-1α. Lastly, we revealed that OSM 
induces VEGF and PAI-1 transcription in a HIF-1α dependent manner. Collectively, our 
data indicate a role for HIF-1α in the OSM-changes in adipocyte metabolism and 
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adipokine secretion in a manner that supports a shift toward glycolytic metabolism and 
vascularization. 
Materials and Methods 
Materials. Dulbecco’s Modified Eagle’s Medium (DMEM), calf bovine serum (CS) 
and Trypsin-EDTA were purchased from Invitrogen. Murine Oncostatin M (OSM) was 
purchased for Sigma. The following antibodies were used for immunoblot analysis: HIF-
1α, HIF-1β, GLUT1, phospho-ERK (Thr202/Tyr204), phospho-AKT (S-473), phospho-
STAT3 (TYR705), total ERK and α-tubulin, were purchased from Cell Signaling. 
Pharmacological inhibitor of ERK (U0126) and pharmacological inhibitor of AKT 
(Wortmannin) were purchased from LC labs. Cycloheximide and Actinomycin D were 
purchased from Sigma. Dicer-substrate siRNA duplexes were purchased from Integrated 
DNA Technologies. Enhanced chemiluminescence (ECL) reagents were obtained from 
Perkin-Elmer Life Sciences. All TaqMan primer probes used in this study were 
purchased from Applied Biosystems.  
 Cell Culture. The murine 3T3-L1 cell line was purchased from Howard Green, 
Harvard Medical School. Cells were propagated in DMEM supplemented with 10% CS 
until reaching density-induced arrest, as previously described. Throughout the study, ‘0h’ 
refers to density arrested cells immediately prior to stimulation as described in figure 
legend. Experiments described herein were conducted in density-arrested 
preadipocytes. All experiments were repeated 2- 3 times to validate results and ensure 
reliability.  
 Immunoblotting. Cell monolayers were washed with phosphate-buffer saline 
(PBS) and scraped into ice-cold lysis buffer containing 0.1 M Tris (pH 7.4), 150 mM 
NaCl, 10% sodium dodecyl sulfate (SDS), 1% Triton X, 0.5% Nonidet P-40 (NP40), 1 
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mM EDTA, 1 mM EGTA. Phosphatase inhibitor (2 µM sodium orthovanadate) and 
protease inhibitors (0.3 µM aprotinin, 21 µM leupetin, 1 µM pepstatin, 50 µM 
phenanthroline, 0.5 µM phenylmethylsulfonyl fluoride) were added to lysis buffer 
immediately prior to cell harvest. Cell lysates were sonicated and centrifuged (15,000g, 
10 min, 4°C), and the supernatant transferred to a fresh tube. Protein content was 
determined by bicinchoninic acid (BCA) procedures according to manufacturer’s (Pierce, 
Rockford, IL) instructions. Equal amounts of whole cell lysate protein were separated by 
SDS-PAGE electrophoresis. Cell lysates were mixed with loading buffer containing 
0.25M Tris (pH6.8), 4% SDS, 10% glycerol, 0.01% bromophenol blue, and 10% 
dithiothreitol, then heated at 80°C for 5 min prior to electrophoresis. Proteins were 
resolved on SDS-polyacylamide gel electrophoresis (PAGE) and transferred to 
polyvinylidene fluoride (PVDF) membranes (Millipore corp., Billerica, MA). After transfer, 
membranes were blocked with 4% milk and probed with indicated primary antibodies 
overnight at 4°C. Membranes were subsequently probed with horseradish peroxidase 
conjugated secondary antibodies for 2 hrs at room temperature. Membranes were 
immersed in ECL and data visualized by autoradiography using CL-XPosure film 
(Pierce).  
 Real-Time RT-PCR. Total RNA was extracted and genomic DNA contamination 
was removed using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA), according to 
manufacturer protocol. Total RNA was quantified with a Nanodrop ND-1000 
spectrophotometer. Total RNA was reverse-transcribed to cDNA in a 10 µl reaction 
volume using a high capacity cDNA reverse transcription kit (Applied Biosystems). The 
reverse transcription (RT) master mix containing RT buffer, deoxyribonucleotide 
triphosphate (dNTP) mix, RT random primers, RNase inhibitor (1.0 U/µl), and MultiScribe 
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RT was added to 1 µg RNA and RNase-free water. Reverse transcription reaction 
conditions followed the protocol (25°C for 10 min, 37°C for 120 min, 85°C for 5 sec, 
followed by 4°C in definitely/ RT complete) and utilized the Gene Amp PCR System 
9700 thermal cycler (Applied Biosystems) for cDNA synthesis. PCR amplification was 
run utilizing the 7500 fast system (Applied Biosystems) that consisted of enzyme 
activation at 95°C for 20 sec, followed by 40 cycles of denaturation at 95°C for 3 sec 
combined with annealing /extension at 60°C for 30 sec. All data were analyzed with the 
ABI 7500 real time PCR system. All TaqMan primer probes used in this study were also 
purchased from ABI. Data were recorded and analyzed with ABI Sequence Detector 
Software and graphs visualized with Excel software. All data were presented as mean ± 
standard error of the mean (SEM) and representative of duplicate determinations. Data 
were normalized to 18S and measured as relative differences using the 2-ΔΔCT method 
as previously described (34,35). Statistical analyses were conducted using SPSS v25. 
Differences in glycolytic gene expression and angiogenic factors were determined via 
student’s t-test where a p-value of <0.05 was considered significant. Knockdown data 
were analyzed using analysis of variance, with Tukey’s post-hoc analysis used when the 
p value for the respective parameter was statistically significant (p < 0.05).  
 Co-immunoprecipitation. Co-immunoprecipitation (co-IP) was performed using 
the Thermo Fisher Scientific Pierce co-IP kit (26149) following the manufacturer's 
protocol. Briefly, total ERK and DUSP4 antibodies were first immobilized for 2 hrs using 
AminoLink Plus coupling resin. Cells were washed with PBS and incubated with IP 
Lysis/Wash buffer containing 25 mM Tris, pH 7.4, 150 mM NaCl, 1% NP40, 1 mM EDTA 
and 5% glycerol on ice. Cell lysates were collected by brief centrifugation (13,000g, 10 
mins, 4°C). The antibody-coupled resin was then washed and incubated with cell lysate 
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at 4°C overnight. After incubation, the resin was again washed and protein complex 
eluted using elution buffer. Protein complexes were then resuspended in loading buffer, 
resolved on SDS-polyacrylamide electrophoresis gel, and immunoblotted as discussed 
above.  
 Glucose Uptake. Glucose uptake was performing using the Glucose-Uptake Glo 
Assay (Promega) following the manufacturer’s protocol. Briefly, cells propaged in 96-well 
culture dishes, grown until density-arrested and treated with OSM at several time points. 
Media was then removed from cells and washed with 100 µl of PBS. 50 µl of 1 mM 2DG 
was added, shaken briefly and incubated for 10 minutes at room temperature. After 
incubation, 25 µl of stop buffer was added and cells were shaken briefly. Following, 25 µl 
of neutralization buffer was added and cells were shaken briefly. Then, 100 µl of 2DG6P 
detection reagent was added, cells were shaken briefly and incubated for 1 hour at room 
temperature. Glucose uptake was then measured by luminescence (BioTek KC4). 
Statistical analyses were conducted using SPSS v25. Differences in glucose uptake 
were determined via student’s t-test where a p-value of 0.05 was considered significant. 
Knockdown data were analyzed using analysis of variance, with Tukey’s post-hoc 
analysis used when the p value for the respective parameter was statistically significant 
(p < 0.05). 
 Lactate Secretion. Extracellular lactate production was performed using the 
Lactate-Glo Assay (Promega) following the manufacturer’s protocol. Briefly, cells were 
propagated in 96-well culture dishes, grown until density-arrested and treated with OSM 
at several time points. Media was then removed and diluted 40-fold in PBS. 50 µl of the 
sample was then transferred to a new 96-well assay plate and 50 µl of Lactate Detection 
Reagent was added to each sample. The plate was then shaken for 30 seconds and 
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incubated at room temperature. Lactate concentration was then recorded by 
luminescence (BioTek KC4). Statistical analyses were conducted using SPSS v25. 
Differences in lacate production were determined via student’s t-test where a p-value of 
0.05 was considered significant. Knockdown data were analyzed using analysis of 
variance, with Tukey’s post-hoc analysis used when the p value for the respective 
parameter was statistically significant (p < 0.05). 
RNA Interference. Dicer-substrate short interfering RNA (siRNA) for HIF-1α 
specific sequences as well as non-targeting sequences were transfected using 
Lipofectamine RNAiMAX transfection reagent according to manufacturer’s (Invitrogen) 
protocol. Briefly, 3T3-L1 preadipocytes were propagated in 6-well culture dishes until 
reaching confluence. Cells were then stimulated with 9 µl Lipofecatime RNAiMAX 
reagent and either 10 µM HIF-1α specific siRNA or non-targeting siRNA for 48 hr. Cells 
were then stimulated with OSM and further analyses were carried out, as described 
above. 
Results 
 Induction of HIF-1α  by CoCl2 and OSM is Dose and Time-Dependent. 
Research has revealed that various cytokines have the ability to up-regulate HIF-1α 
(30,36). In fact, in a hepatic cell line, OSM significantly increases the induction of HIF-1α 
under normoxic conditions (32). Evidence demonstrates that the expansion of adipose 
tissue causes hypoxia, which leads to increased HIF-1α protein stability and that as 
humans become obese, OSM protein expression also increases (4,8,26). Although both 
hypoxia and OSM are regulated during conditions of obesity and a link between the two 
has been established in other cell types, little is known about the effect of OSM on HIF-
1α in adipocytes. To first establish that the well-known hypoxia mimetic, CoCl2 stabilizes 
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HIF-1α protein, we performed a time course and dose response. Preadipocytes (PAs) 
were either stimulated with 100µM CoCl2 and harvested over time or stimulated with 
varying doses of CoCl2 and harvested at 6 hr. Lysates were immunoblotted for HIF-1α 
and its well-known target, GLUT1. As illustrated in Fig.2.1B, HIF-1α was stabilized at 1 
hr and continued to increase through 24 hr. Additionally, CoCl2 had a dose-dependent 
effect on HIF-1α (Fig.2.1A). These increases were followed by a similar induction of 
GLUT1, which was both increased over time and in dose-dependent manner. To 
determine if OSM induces HIF-1α similar to CoCl2, PAs were either stimulated with 1nM 
OSM and harvested over time or stimulated with varying doses and harvested at 6 hr. 
(Fig.2.1C&D). As shown in Fig. 2.1C, OSM increased HIF-1α and GLUT1 dose-
dependently. Data also reveal (Fig.2.1D) that OSM increased HIF-1α to the same extent 
as CoCl2, but in a transient manner. This was followed by an induction of the 
downstream HIF-1α target, GLUT1. These data indicate the estimated ED50 of OSM of 
1nM leads to HIF-1α protein accumulation equivalent to that shown for the well-known 
hypoxia mimetic, CoCl2.   
OSM Induces HIF-1α  at the Level of Transcription and not Protein Stability. 
It is well known that HIF-1α is continually synthesized and degraded under normoxia and 
that hypoxia or hypoxia mimetics, such as CoCl2, enhance HIF-1α by blocking 
proteasomal degradation, leading to protein accumulation (8,10,37). In some cell types, 
OSM and other cytokines increase HIF-1α at the level of transcription (30–32,38). 
Mechanisms by which HIF-1α is regulated in adipocytes remain largely unknown. Thus, 
we explored mechanisms by which OSM increases HIF-1α protein in 3T3-L1 PAs. 
Density-arrested PAs were stimulated with OSM or CoCl2 and examined for HIF-1α 
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mRNA and protein expression. Total RNA and whole cell lysates were collected over 
time and HIF-1α mRNA and protein expression was examined via RT-PCR and 
immunoblot analysis, respectively. As expected, CoCl2 caused a sustained induction of 
HIF-1α protein (Fig.2.2A), but had no significant effect on mRNA expression of HIF-1α 
(Fig.2.2B). However, OSM significantly increased HIF-1α mRNA (Fig.2.2C) and protein 
expression in a transient manner (Fig.2.2A). These data suggest that OSM regulates 
HIF-1α at the level of transcription, while CoCl2 regulates HIF-1α protein stability. 
Additionally, RT-PCR indicated that both CoCl2 and OSM resulted in an increase in 
transcription of GLUT1 (Fig.2.2D&E), suggesting that induction HIF-1α by either agonist 
is functional.  To confirm that OSM does not stabilize HIF-1α protein, HIF-1α was 
maximally induced in density-arrested PAs by 3 hrs OSM and CoCl2 pretreatment and 
then stimulated with protein synthesis inhibitor cycloheximide (CHX) to prevent 
additional protein synthesis. Whole cell lysates were collected over time and 
immunoblotted for HIF-1α. As illustrated in Fig.2.3A, induction of HIF-1α by OSM was 
diminished by 1 hr, whereas induction of HIF-1α by CoCl2 remained largely detectable at 
1 hr. The faster rate of HIF-1α decay by OSM indicates that induction is not due to 
increased protein stability. To further confirm the regulation of HIF-1α by OSM, density-
arrested PAs were stimulated concurrently with the transcription inhibitor, actinomycin D 
(AD) and OSM or CoCl2. AD had no effect on HIF-1α protein in cells stimulated with 
CoCl2, but eliminated HIF-1α levels in cells stimulated with OSM (Fig.2.3B). These data 
clearly demonstrate that OSM-mediated HIF-1α induction is due to transcription, while 
CoCl2-mediated HIF-1α induction is due to protein stabilization.  
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 OSM-Induced HIF-1α  Interacts with HIF-1β  to Form Functional 
Heterodimeric Complex. For HIF-1α to act as a functional transcription factor, it must 
be translocated to the nucleus and heterodimerized with HIF-1β (10,12,39). To establish 
the protein-protein interaction and confirm that the OSM-induced HIF-1α is functional, 
we stimulated density-arrested PAs with OSM, and harvested lysates at 6 hrs. Lysates 
were immunoprecipitated for HIF-1β and immunoblotted for HIF-1α and HIF-1β. As 
illustrated in Fig.2.4, under basal conditions where there was no OSM stimulation, HIF-
1β did not co-immunoprecipitate with HIF-1α (lane 1). OSM stimulation for 6 hrs led to 
HIF-1α induction and HIF-1α-HIF-1β co-immunoprecipitation (lane 2). Non-specific 
binding of lysate proteins to agarose coupling resin was ruled out (lane 3). These data 
demonstrate that OSM-induced HIF-1α interacts with constitutively expressed HIF-1β to 
form the heterodimeric complex known to impart functional activity.  
OSM Activates STAT, ERK and AKT Signaling Pathways. Previous research 
has established that OSM activates the janus kinase/signal transducer of activation 
(JAK/STAT), all three mitogen-activated protein kinases (MAPKs) and the 
(phosphoinositie-3-kinase-protein kinase/AKT (P13K/AKT) signaling pathways (40,41). 
The activation of these signaling pathways can have important implications. For 
example, some research suggests that OSM inhibits adipogenesis specifically through 
the RAS/ERK and STAT5 signaling pathways (42). Importantly, in liver cells, OSM-
mediated HIF-1α up-regulation is dependent on STAT3 (32). To confirm that these well-
known signaling pathways are activated in 3T3-L1 PAs, density-arrested cells were 
stimulated with OSM and whole cell lysates were collected over time. As shown in 
Fig.2.5, OSM caused a rapid increase in the phosphorylation of STAT3, ERK and AKT. 
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These data suggest that these specific signaling molecules may be involved in the 
downstream effects of OSM, such as changes in gene expression.  
 OSM-Induced HIF-1α  is Dependent on ERK and AKT. Our data suggest that 
the phosphorylation of STAT3, ERK and AKT are all significantly increased with OSM. 
Previous studies have focused on the role of STAT3 in OSM-mediated HIF-1α 
regulation. Research has indicated that STAT3 is critical for the up-regulation of HIF-1α 
by OSM (32). However, there is a lack of research investigating a role for both ERK and 
AKT in OSM-mediated HIF-1α induction. Therefore, we sought to examine the 
importance of ERK and AKT in the up-regulation of HIF-1α. Density-arrested PAs were 
pretreated with MEK-inhibitor, U0126 or P13K-inhibitor Wortmannin for 1 hr to allow for 
complete inhibition of p-ERK and p-AKT, respectively. PAs were then stimulated with 
OSM and lysates were collected over time and immunoblotted for p-ERK, p-AKT, p-
STAT3 and HIF-1α. As illustrated in Fig.2.6, the addition of U0126 reduced 
phosphorylation of ERK, as well as the levels of HIF-1α, indicating that p-ERK plays an 
important role in OSM-mediated HIF-1α up-regulation. Interestingly, the inhibition of p-
ERK also affected the phosphorylation of AKT and STAT3, revealing that there is 
crosstalk between signaling pathways. In Fig.2.7, data show that pretreatment with 
Wortmannin completely inhibited the phosphorylation of AKT, which greatly reduced 
HIF-1α induction. Inhibition of AKT also altered the phosphorylation of ERK and STAT3, 
reiterating our finding that there is crosstalk between signaling pathways. To further 
emphasize the importance of the ERK and AKT pathways in OSM-mediated induction of 
HIF-1α, PAs were pretreated with the combination of U0126 and Wortmannin for 1 hr 
before stimulation with OSM and cell lysates were collected over time and 
immunoblotted for p-ERK, p-AKT, p-STAT3 and HIF-1α. As illustrated in Fig.2.8, 
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phosphorylation of both ERK and AKT were significantly reduced, while there was little 
change in p-STAT3. Although p-STAT3 remained unchanged, the inhibition of ERK and 
AKT, nearly abolished OSM-induced HIF-1α. These data confirm ERK and AKT as 
critical signaling molecules for the up-regulation of HIF-1α by OSM, independent of 
STAT3.  
CoCl2 and OSM have a Synergistic Effect on HIF-1α . Data presented above 
demonstrate that both CoCl2 and OSM induce HIF-1α but do so by different 
mechanisms. Research indicates that HIF-1α regulates genes involved in a variety of 
processes such as angiogenesis, inflammation, proliferation, differentiation and glucose 
metabolism (8,13,43,44). Therefore, we hypothesized that if CoCl2 and OSM induce HIF-
1α by different mechanisms, the stimulation of PAs with both CoCl2 and OSM would 
cause a synergistic effect on HIF-1α. An even greater increase in HIF-1α protein would 
likely lead to an increase in the downstream effects of HIF-1α seen during conditions of 
obesity when both hypoxia and inflammation are present. To test this hypothesis, 
density-arrested PAs were stimulated with CoCl2 and OSM in conjunction and whole cell 
lysates were collected over time and immunoblotted for HIF-1α, as well as GLUT1. As 
illustrated in Fig.2.9, immunoblotting reveals that stimulation with CoCl2 and OSM 
caused a synergistic effect on HIF-1α and GLUT1. These data suggest that during 
obesity, when both hypoxia and inflammation are present, the synergistic effect of these 
conditions on HIF-1α could lead to an amplifying effect on downstream targets of HIF-
1α. 
OSM Increases Glycolytic Gene Transcription, Glucose Uptake and Lactate 
Secretion. OSM is a pleiotropic cytokine that has been implicated in inflammation, 
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differentiation, insulin signaling, lipid metabolism and more recently has been shown to 
be involved in the metabolic reprogramming in some cell types (26,33,45). This is in 
congruence with research suggesting that some cytokines, such as TNF-α and IL-6, 
have the ability to regulate mitochondrial bioenergetics. (23) Additionally, our preliminary 
data indicate that OSM increases GLUT1 (Fig.2.1D), which suggests that OSM may shift 
from oxidative to glycolytic metabolism.  Therefore we investigated the effect of OSM on 
the enzymes within the glycolytic pathway, as well as the effect on glucose uptake and 
lactate production. PAs were stimulated with OSM and total RNA was collected over 
time and analyzed for various glycolytic genes. As illustrated in Fig.2.10, OSM 
significantly up-regulated all of the genes encoding for enzymes in the glycolytic 
pathway. While we were unable to determine the effect of OSM on G6P isomerase, 
OSM increased hexokinase-2 (HK2), phosphofructokinase-1 (PFKL), aldolase A 
(ALDOA), trieosphosphate isomerase (TPI1), glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), phosphoglycerate kinase (PGK1), phosphoglycerate mutase 
(PGAM1), enolase A (ENOA) and pyruvate kinase-M (PKM). Additionally, OSM 
increased gene expression of pyruvate dehydrogenase kinase 1 (PDK1), which inhibits 
pyruvate dehydrogenase (PDH) from converting pyruvate to acetyl CoA for entrance into 
the TCA cycle. This is consistent with the finding that OSM increases lactate 
dehydrogenase-A (LDHA), as well as glucose transporter GLUT1 and lactate 
transporters monocarboxylate 1 and 4 (MCT1, MCT4) (Fig.2.11). These data indicate 
that OSM transcriptionally up-regulates enzymes in the glycolytic pathway, as well as 
enzymes involved in anaerobic metabolism, such as glucose and lactate transporters 
(Fig.2.12). We further sought to determine whether the effect of OSM on glycolysis led to 
changes in glucose uptake and lactate secretion. PAs were stimulated with OSM and 
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glucose uptake was analyzed over time by luminescence. Data further revealed that 
OSM significantly increased glucose uptake (Fig.2.13). Moreover, stimulation of PAs 
with OSM for 24 hr led to an increase in lactate secretion as measured by luminescence 
(Fig.2.14). Collectively, these data suggest that OSM affects adipocyte bioenergetics by 
increasing anaerobic metabolism as would be expected for hypoxia, but not under 
normoxic conditions. 
OSM-Induced HIF-1α  is Involved in the Metabolic Reprogramming of 
Adipocytes. A well-known adaptation to hypoxia is the switch from oxidative to 
glycolytic metabolism through HIF-1α (8,10,46). When too little oxygen is present, 
aerobic metabolism is decreased, so in order to maintain ATP production, HIF-α 
increases anaerobic oxidation (46). Our data suggest that OSM causes a switch from 
oxidative to glycolytic metabolism. In hepatocytes, OSM is able to alter metabolic 
parameters in a HIF-1α-dependent manner (33). However, research has not fully linked 
OSM and HIF-1α to metabolic changes in adipocytes. Therefore, we examined the role 
for HIF-1α in OSM-mediated effects on metabolic reprogramming. PAs were transfected 
with siRNA targeted to HIF-1α or non-targeting control sequences for 48 hr prior to 
stimulation with OSM. Total RNA and whole cell lysates were harvested over time and 
analyzed for mRNA abundance of HIF-1α and the previously described glycolytic genes. 
As illustrated in Fig.2.16, each gene was analyzed at a time that fit the peak of induction 
as observed from previous data. Data indicated that HIF-1α gene expression (Fig.2.15A) 
and protein (Fig.2.15B) was markedly induced by OSM in cells transfected with control 
siRNA. In contrast, induction of HIF-1α mRNA and protein was significantly suppressed 
in cells treated with HIF-1α targeting siRNA (Fig.2.15A). As illustrated in Fig.2.15C, 
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knockdown of HIF-1α significantly reduced the OSM-mediated up-regulation of the 
genes encoding enzymes in the glycolytic pathway including HK2, PFKL, ALDOA, TPI1, 
GAPDH, PGK1, PGAM1, ENOA, as well as PDK1, compared to cells transfected with 
non-targeting siRNA and stimulated with OSM. The only gene in the glycolytic pathway 
not affected by siRNA targeted to HIF-1α was PKM. Additionally, HIF-1α knockdown 
significantly reduced the OSM-mediated increases in GLUT1, LDHA and MCT4. In 
contrast to these findings, HIF-1α knockdown significantly increased OSM-mediated up-
regulation of MCT1 compared to non-targeting siRNA. To further support a role for HIF-
1α in the OSM-induced shift in metabolism toward glycolytic flux, PAs were transfected 
with siRNA targeted to HIF-1α or non-targeting control sequences for 36 hr prior to 
stimulation with OSM. Glucose uptake was measured by luminescence at 12 hr post-
OSM treatment. As shown in Fig.2.16, glucose uptake was significantly increased in 
cells transfected with control siRNA, while knockdown of HIF-1α prevented the OSM-
mediated increase in glucose uptake. Similarly, PAs were transfected with both siRNA 
for HIF-1α and non-targeting control for 24 hr before treatment with OSM and lactate 
secretion was measured by luminescence at 24 hr post-OSM stimulation. Control siRNA 
cells treated with OSM had a significant increase in lactate secretion, while cells 
transfected with siRNA for HIF-1α and treated with OSM did not significantly increase 
lactate secretion compared to cells with HIF-1α siRNA only (Fig.2.17). These data 
suggest that the OSM-mediated increase in glycolytic function, including an increase in 
glycolytic gene transcription, glucose uptake and lactate secretion, is dependent on HIF-
1α. 
 OSM Stimulation Increases VEGF and PAI-1. It is well accepted that 
increasing obesity leads to dysregulated adipokine production (20). These adipokines 
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are involved in a variety of physiological processes such as glucose homeostasis, insulin 
sensitivity, lipid metabolism and angiogenesis (47,48). The capacity of adipose tissue to 
continually expand requires a proportional increase in vascularization to meet its 
increasing energy demands (49). The major regulator of this vascularization is VEGF. In 
particular, it is well accepted that VEGF-A increases vascularization in white adipose 
tissue (50,51). On the other hand, VEGF-B acts as a vascular survival factor and VEGF-
C and VEGF-D are mainly involved in lymphangiogenesis (52). Research has shown 
that in human adipocytes, OSM increases mRNA and protein production of VEGF. To 
confirm that OSM increases VEGF in our 3T3-L1 model, density-arrested PAs were 
stimulated with OSM and total lysates were collected over time and analyzed for relative 
VEGF-A mRNA abundance. Data revealed the OSM significantly induces VEGF-A in a 
transient manner but had no effect on VEGF-B or VEGF-C (Fig.2.18). Research also 
indicates that OSM induces PAI-1, an adipokine involved in both angiogenesis and 
insulin resistance (28,53,54). To elucidate the impact of OSM on PAI-1, PAs were 
stimulated with OSM and total RNA was collected over time and analyzed for relative 
PAI-1 abundance.  Similar to the effect on VEGF-A, treatment with OSM caused a 
transient induction of PAI-1 (Fig.2.18).  
 Role for HIF-1α  in OSM-Induced Expression of VEGF and PAI-1. Data 
presented above demonstrate that OSM leads to dysregulated adipokine production. 
Research also shows that hypoxia regulates the expression of adipokines, such as 
VEGF, PAI-, IL-6, MMP-2 and MMP-9, and that many of these hypoxia sensitive genes 
are dependent on the induction of HIF-1α (15,20,21,55). To investigate a role for HIF-1α 
in OSM-mediated alterations in adipokine expression, PAs were transfected with siRNA 
targeted to HIF-1α or non-targeting control sequences for 48 hr before stimulation with 
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OSM. Total RNA was collected over time and analyzed for mRNA abundance of VEGF-
A and PAI-1 at a time that fit the peak of induction as observed from previous data. Data 
indicated that HIF-1α gene expression was markedly induced by OSM in cells 
transfected with control siRNA. However, as illustrated in Fig.2.19, specific knockdown 
of HIF-1α significantly reduced the OSM-mediated up-regulation of VEGF-A and PAI-1 
compared to control. These data demonstrating that OSM stimulated VEGF-A and PAI-1 
expression is dependent on HIF-1α support the premise that hypoxia is directly linked to 
inflammation and an angiogenic response. 
Discussion 
In this investigation, we demonstrated a role for HIF-1α in OSM-mediated 
regulation of gene expression in 3T3-L1 adipocytes. First, we report that induction of 
HIF-1α by OSM and hypoxia mimetic CoCl2 is dose and time dependent. Importantly, 
HIF-1α was induced to the same extent by OSM as CoCl2. Second, we show that the 
induction of HIF-1α by OSM is regulated at the level of transcription through STAT, ERK 
and AKT signaling pathways. Of these signaling pathways, OSM-induced HIF-1α was 
dependent on ERK and AKT. Third, we confirm that HIF-1α interacts with HIF-1β to form 
a functional heterodimeric complex and act as a transcription factor. Fourth, we found 
that the addition of both CoCl2 and OSM has a synergistic effect on HIF-1α. Fifth, we 
present evidence that OSM increases glycolytic gene transcription, glucose uptake and 
lactate secretion and that HIF-1α is involved in this metabolic reprogramming of 
adipocytes. Finally, we show that OSM increases the expression of VEGF and PAI-1 
and that HIF-1α plays a role in the induction of these angiogenic adipokines. 
Collectively, data presented in this report demonstrate that OSM transcriptionally 
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regulates HIF-1α and OSM regulates glycolytic gene expression, glucose uptake, lactate 
production and angiogenic adipokine expression in a HIF-1α dependent manner in 3T3-
L1 adipocytes. 
 It is well established that both hypoxia and inflammation are present in obese 
adipose tissue and that these conditions lead to dysregulated glucose and lipid 
metabolism, insulin resistance and overall adipocyte dysfunction (56–60). It’s been 
proposed that hypoxia initiates the inflammatory response in adipose tissue (20). 
Hypoxic conditions contribute to many functional changes through the activation of 
transcription factor, HIF-1α (8). Investigations in the past have extensively focused on 
the effects of HIF-1α on adipokine secretion (15,21). Accumulating evidence now 
suggests that adipokines have the ability to regulate HIF-1α, even under normoxic 
conditions (30,31,38). Recent studies have shown that as obesity increases, the 
inflammatory cytokine, OSM increases and correlates with obesity and insulin sensitivity 
(26). Data in this investigation present evidence that OSM increases the abundance of 
HIF-1α mRNA and protein, supporting the premise that HIF-1α can be regulated by 
adipokines under normoxic conditions. In comparison to the up-regulation of HIF-1α by 
CoCl2, which was sustained, induction of HIF-1α by OSM was transient. However, we 
found that HIF-1α protein abundance induced by OSM was increased to the same extent 
of CoCl2, which demonstrates the significance of the impact of OSM on this transcription 
factor. While the regulation of HIF-1α by hypoxia is well established, mechanisms by 
which cytokines induce HIF-1α remain poorly understood. Data presented above 
demonstrate that OSM increases HIF-1α mRNA, but does not effect protein stability. 
Blockade of transcription with Actinomycin D inhibited OSM induced HIF-1α, but had no 
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effect on HIF-1α protein induced by CoCl2. Consistent with our observation, Vollmer and 
colleague also reported that OSM induces HIF-1α in a transcription-dependent manner 
in hepatocytes (32). In some cell types, it has been shown that the HIF-1α induction by 
cytokines is a functional transcription factor (30–32,38). Our data confirm that OSM-
induced HIF-1α interacts with HIF-1β to form a functional heterodimeric complex. Taken 
together, our data demonstrate that the induction of HIF-1α by OSM is regulated at the 
level of transcription and activates a fully functional transcription factor, which suggests 
that the effects of OSM on adipocyte function may be related, in part, to the induction of 
HIF-1α.  
 Evidence from previous studies indicates that OSM exerts its pleiotropic effects 
through a variety of signaling pathways. For example, OSM has been reported to 
activate the JAK/STAT, (MAPK) ERK1/ERK2, p38, c-Jun N-terminal, and protein kinase 
C delta (PKCδ) signaling pathways (32,40,41). Our findings demonstrate that OSM 
quickly increases STAT, ERK and AKT signaling pathways and may be involved in the 
induction of HIF-1α by OSM. Previous research has concentrated on the activation of 
the JAK/STAT pathway, including both STAT3 and STAT5, in response to OSM (27,32). 
Moreover, Vollmer and colleague have found that the induction of HIF-1α by OSM is 
dependent on STAT3 phosphorylation (32). In contrast, we found that the suppression of 
both ERK and AKT with U0126 and Wortmannin, respectively, completely inhibited the 
induction of HIF-1α by OSM, independent of STAT3. Collectively, these data suggest 
that ERK and AKT are critical signaling molecules for the OSM-mediated induction of 
HIF-1α.  
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 Adipocyte dysfunction is characterized by a conglomeration of factors that are 
implicated during obesity such as reduced insulin sensitivity, increased hypoxia, 
increased adipokines, increased apoptosis, increased autophagy and increased reactive 
oxygen species (ROS) (56). Like hypoxia, hypoxia-mimetic, CoCl2 stabilizes the HIF-1α 
protein, whereas our data show that OSM increases HIF-1α at the level of transcription. 
Our data demonstrate that the combination of both CoCl2 and OSM has a synergistic 
effect on HIF-1α, causing a greater increase in the abundance of this transcription factor 
with the combination of treatments than either treatment alone. While no other study has 
addressed the amplifying effect of both hypoxia and OSM on HIF-1α in adipocytes, 
these data suggest that during adipose tissue expansion, the increase and downstream 
effects of HIF-1α on adipocyte dysfunction may also be attributed to inflammation, not 
just hypoxia.  
 It is well established that a critical metabolic adaptation to hypoxia is the HIF-1α-
dependent switch from oxidative to glycolytic metabolism (8,10,46). HIF-1α increases 
glycolytic metabolism through a variety of mechanisms including increased PDK1 
activity, induction of GLUT1, GLUT3, GLUT5, increased glucose uptake, regulation of 
glycolytic gene expression, as well as increased expression of lactate secretion and 
MCT1 and MCT4 expression (14,16–18,21,55,61,62). More recently, studies have found 
that some cytokines, such as TNF-α, IL-6 and IL-1β increase glucose transporters, 
glucose uptake, cause changes in basal respiration and increase lactate efflux (23,63). 
Data presented in this investigation reveal for the first time that OSM significantly up-
regulated all genes encoding for enzymes in the glycolytic pathway, as well as PDK1, 
LDHA, GLUT1, MCT1 and MCT4. Survival of cells during hypoxia requires the 
downstream targets of HIF-1α to be up-regulated to cope with hypoxic stress. Greijer 
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and colleague found that HIF-1α significantly regulated all glycolytic enzymes (18). Our 
data provides evidence that HIF-1α is involved, in part, in the OSM-mediated induction 
of glycolytic enzymes. Not all enzymes up-regulated by OSM were dependent on HIF-
1α, which may be explained by the fact that OSM is a pleiotropic cytokine. Furthermore, 
we found that siRNA targeted to HIF-1α without OSM stimulation significantly reduced 
the level of gene expression of glycolytic enzymes. This raises the possibility that 
several of these glycolytic enzymes depend on a basal level of HIF-1α to stay up-
regulated. Previous research suggests that hypoxia initiates the hypoxic response. 
However, our data suggest that inflammation initiates the hypoxic response, via HIF-1α. 
Furthermore, we found that OSM led to an increase in glucose uptake, as well as lactate 
secretion, both of which were dependent on the induction of HIF-1α. Therefore, these 
data demonstrate that the OSM-mediated switch to glycolytic function is dependent on 
HIF-1α. This finding suggests that adipocytes with increased levels of OSM require the 
induction HIF-1α for survival during inflammatory stress.  
 It is widely accepted that hypoxia causes an increase in adipokine production 
and that changes in the expression of these adipokines correspond to the levels of HIF-
1α (15,20). For instance, exposure to low O2 conditions in adipocytes increases VEGF, 
IL-6 and PAI-1. (21) It has been hypothesized that the effect of hypoxia on adipokine 
production is to stimulate angiogenesis for increased blood flow to the adipose tissue. 
VEGF and to some extent, PAI-1 are major regulators of angiogenesis. Interestingly, 
treatment of adipocytes with OSM increases both VEGF and PAI-1 (28,29). Consistent 
with these findings, our data indicate that OSM increases VEGF and PAI-1 and are 
dependent on HIF-1α for induction. These data suggest that HIF-1α is the mechanism 
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by which OSM up-regulates VEGF and PAI-1 and that these adipokines may be induced 
to increase angiogenesis for metabolic adaptation to hypoxic and inflammatory stress. 
Based on these findings, we developed the following working model (Fig.2.20), where 
hypoxia and inflammation during obesity lead to the accumulation of HIF-α to regulate 
metabolic adapation. 
 In summary, this study is the first investigation showing that the transcriptional 
regulation of HIF-1α by OSM leads to changes in mitochondrial bioenergetics and 
adipokine expression in adipocytes. Previous research has shown that both hypoxia and 
increased OSM expression is present under conditions of obesity. Data presented here 
show that OSM leads to a transient, yet strong induction of HIF-1α, regulated at the level 
of transcription that is dependent on ERK and AKT signaling pathways, and not protein 
stability. Additionally, data suggests that OSM leads to a switch from aerobic to glycolytic 
metabolism as well as an increase in expression of angiogenic factors that is dependent 
on HIF-1α. Our data also demonstrate that the combination of hypoxia and inflammation, 
such as found during obesity, causes a synergistic effect on HIF-1α, which causes a 
synergistic effect on downstream targets, such as GLUT1. Collectively, data presented 
here demonstrate a mechanistic link between inflammation and hypoxia. As 
investigations continue, elucidating the effects of HIF-1α by OSM during obesity may 
contribute to a better understanding of how HIF-1α contributes to both survival and 
adipocyte dysfunction. This understanding may then lead to therapeutic targets for the 
treatment of obesity-related insulin resistance and adipocyte dysfunction.  
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Figure 2.1. Induction of HIF-1α  by CoCl2 and OSM is Dose and Time-Dependent. 
Preadipocytes were stimulated with varying doses of CoCl2 and lysates were collected at 
6h (A) or with 100µM CoCl2 and collected at the indicated time (B). C) Preadipocytes 
were stimulated with varying doses of OSM and collected at 6h or stimulated with 1nM 
OSM and collected over time (D). Cell lysates were analyzed for protein expression of 









































Figure 2.2. OSM Induces HIF-1α  Transcription and Protein. Preadipocytes were 
stimulated with 100µM CoCl2 or 1nM OSM. A) Cell lysates were collected over time and 
protein expression of HIF-1α and GLUT1 was analyzed via immunoblotting. B) Total 
RNA was collected and gene expression of HIF-1α and GLUT1 was measured via qRT-
PCR. All data were normalized to 18S rRNA and expressed relative to untreated cells 









Figure 2.3. OSM-Mediated HIF-1α  Up-Regulation is Due to Transcription and not 
Protein Stability. A) Preadipocytes were pretreated with 100µM CoCl2 or 1nM OSM for 
3h before stimulation with 5µM cycloheximide (CHX). Cell lysates were collected over 
time post-CHX and protein expression of HIF-1α and α-tubulin was analyzed via 
immunoblotting. B) Preadipocytes were stimulated with either 100µM CoCl2 or 1nM OSM 
in the absence or presence of 1 ng/ml Actinomycin D (AD). Cell lysates were collected 




Figure 2.4. OSM-Induced HIF-1α  Interacts with HIF-1β  to Form Functional 
Heterodimeric Complex. Cell lysates were harvested from preadipocytes at 0h and 6h 
post-OSM (1nM), immunoprecipitated for HIF-1β (lane 1 and 2) and immunoblotted for 




Figure 2.5. OSM Activates STAT, ERK and AKT Signaling Pathways. Preadipocytes 
were stimulated with 1nM OSM and cell lysates were collected over time. Protein 





Figure 2.6. OSM-Induced HIF-1α  is Dependent on ERK. Preadipocytes were 
stimulated with 1nM OSM in the absence or presence of 40µM U0126 (1h pretreatment). 
Cell lysates were harvested at indicated times and immunoblotted for p-ERK, p-AKT, p -






Figure 2.7. OSM-Induced HIF-1α  is Dependent on AKT. Preadipocytes were 
stimulated with 1nM OSM in the absence or presence of 0.5µM Wortmannin (1h 
pretreatment). Cell lysates were harvested at indicated times and immunoblotted for p-






Figure 2.8. OSM-Induced HIF-1α  is Dependent on ERK and AKT. Preadipocytes 
were stimulated with 1nM OSM in the absence or presence of 40µM U0126 and 0.5µM 
Wortmannin (1h pretreatment). Cell lysates were harvested at indicated times and 






Figure 2.9. CoCl2 and OSM have a Synergistic Effect. Preadipocytes were stimulated 
with 100µM CoCl2, 1nM OSM or the combination of both CoCl2 and OSM. Cell lysates 






Figure 2.10. OSM-Mediated Up-Regulation of Glycolytic Genes. Preadipocytes were 
stimulated with 1nM OSM. Cell lysates were collected over time and gene expression of 
all glycolytic genes and PDK1 was analyzed via qRT-PCR. Data were normalized to 18S 
rRNA and expressed relative to untreated PAs (0h). Statistical significance was 
determined by Student’s t-test (* p<0.05). 
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Figure 2.11. OSM Regulates Genes Associated with Glycolysis. Preadipocytes were 
stimulated with 1nM OSM. Cell lysates were collected over time and gene expression of 
GLUT1, LDHA, MCT1 and MCT4 was analyzed via qRT-PCR. Data were normalized to 
18S rRNA and expressed relative to untreated PAs (0h). Statistical significance was 






Figure 2.12. OSM Increases Glucose Uptake. Preadipocytes were stimulated with 
OSM at the indicated times and glucose uptake was measured by luminescence. 
Statistical significance was determined by Student’s t-test (* p<0.05). 
 
 
Figure 2.13. OSM Increases Extracellular Lactate Production. Preadipocytes were 
stimulated with OSM for 24h and extracellular lactate production was measured by 







Figure 2.14. Role for HIF-1α  in OSM-Mediated Metabolic Adaptation. Preadipocytes 
were transfected with Lipofectamine RNAiMAX reagent in the presence of non-targeting 
control siRNA or siRNA for HIF-1α for 48h prior to stimulation with OSM. A) Cell lysates 
were harvested at 3h post-OSM and analyzed for HIF-1α and t-ERK via immunoblotting. 
B) Cell lysates were harvested for total RNA and mRNA expression of HIF-1α analyzed 
via qRT-PCR. Data were normalized to 18S rRNA and changes in gene expression 
measured as fold changes relative to untreated control siRNA (si scr (-)). Statistical 
differences were determined by ANOVA. Tukey’s post-hoc analysis was performed with 















Figure 2.14. Role for HIF-1α  in OSM-Mediated Metabolic Adaptation (continued). 
Preadipocytes were transfected with Lipofectamine RNAiMAX reagent in the presence of 
non-targeting control siRNA or siRNA for HIF-1α for 48h prior to stimulation with OSM. 
C) Cell lysates were harvested for total RNA and mRNA expression of all glycolytic 
genes analyzed via qRT-PCR. Data were normalized to 18S rRNA and changes in gene 
expression measured as fold changes relative to untreated control siRNA (si scr (-)). 
Statistical differences were determined by ANOVA. Tukey’s post-hoc analysis was 






















Figure 2.14. Role for HIF-1α  in OSM-Mediated Metabolic Adaptation (continued). 
Preadipocytes were transfected with Lipofectamine RNAiMAX reagent in the presence of 
non-targeting control siRNA or siRNA for HIF-1α for 48h prior to stimulation with OSM. 
D) Cell lysates were harvested for total RNA and mRNA expression of GLUT1, LDHA, 
MCT1 and MCT4 analyzed via qRT-PCR. Data were normalized to 18S rRNA and 
changes in gene expression measured as fold changes relative to untreated control 
siRNA (si scr (-)). Statistical differences were determined by ANOVA. Tukey’s post-hoc 
analysis was performed with the p value for the respective parameter was statistically 

















Figure 2.15. Role for HIF-1α  in OSM-Mediated Glucose Uptake. Preadipocytes were 
transfected with Lipofectamine RNAiMAX reagent in the presence of non-targeting 
control siRNA or siRNA for HIF-1α for 48h prior to stimulation with OSM. Glucose uptake 
was measured via luminescence at 12h post-OSM. Statistical differences were 
determined by ANOVA. Tukey’s post-hoc analysis was performed with the p value for 
the respective parameter was statistically significant (p<0.05). 
 
 
Figure 2.16. Role for HIF-1α  in OSM-Mediated Lactate Production. Preadipocytes 
were transfected with Lipofectamine RNAiMAX reagent in the presence of non-targeting 
control siRNA or siRNA for HIF-1α for 48h prior to stimulation with OSM. Lactate 
production was measured via luminescence at 24h post-OSM. Statistical differences 
were determined by ANOVA. Tukey’s post-hoc analysis was performed with the p value 





Figure 2.17. Summary of Glycolytic Genes Up-Regulated by OSM and Dependent 











Figure 2.18. OSM Stimulation Increases VEGF and PAI-1. Preadipocytes were 
stimulated with 1nM OSM. Cell lysates were collected over time and gene expression of 
VEGFA, VEGFB, VEGFC and PAI-1 was analyzed via qRT-PCR. Data were normalized 
to 18S rRNA and expressed relative to untreated PAs (0h). Statistical significance was 





Figure 2.19. Role for HIF-1α  in OSM-Induced Expression of VEGF and PAI-1. 
Preadipocytes were stimulated with 1nM OSM. Cell lysates were collected over time and 
gene expression of VEGF and PAI-1 was analyzed via qRT-PCR. Data were normalized 
to 18S rRNA and changes in gene expression measured as fold changes relative to 
untreated control siRNA (si scr (-)). Statistical differences were determined by ANOVA. 
Tukey’s post-hoc analysis was performed with the p value for the respective parameter 










Figure 2.20. Proposed Working Model for Regulation and Function of HIF-1α  
during Obesity in Response to Hypoxia and OSM in 3T3-L1 Adipocyte Cell Model. 
During obesity, the combination of tissue hypoxia and increased production of 
inflammatory marker OSM leads to an increased accumulation of HIF-1α by different 
mechanisms. Functional HIF-1α then leads to metabolic adaptations within the adipocyte 
such as increased neovascularization by induction of VEGF-A and PAI-1 and increased 
glycolytic function through increased glycolytic gene transcription, glucose uptake and 
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Knowledge concerning the regulation of proliferation and differentiation 
(collectively termed hyperplasia) of preadipocytes (PAs) during obesity is critical for 
understanding adipose tissue remodeling and its related function. A growing body of 
evidence indicates that the local hypoxia and cytokine secretion accompanying obesity 
affects adipose tissue hyperplasia. Using proliferating and differentiating 3T3-L1 PAs, 
this study examined the impact of the inflammatory cytokine, Oncostatin M (OSM) on 
adipocyte cell growth and differentiation. Data presented here demonstrate that OSM 
inhibited proliferation of subconfluent PAs while concurrently reducing cyclin D1, cyclin 
A, cyclin B1 and p-RB, suggesting OSM affects cell growth by a mechanism related to 
cell cycle. We further demonstrate that OSM inhibited differentiation during mitotic clonal 
expansion (MCE) by inhibiting PPARγ (peroxisome proliferator-activated receptor γ), 
C/EBPα (CCAAT/enhancer-binding protein α), aP2 (adipocyte protein 2) and ADPN 
(adiponectin). Additionally, OSM dramatically reduced cyclin D1 during differentiation. 
Moreover, we show that OSM induces hypoxia inducible factor-1α (HIF-1α) during 
differentiation and that HIF-1α-specific knockdown partially restores PPARγ, C/EBPα, 
aP2 and cyclin D1. Collectively, these results suggest that HIF-1α plays a mechanistic 





 According to the World Health Organization (WHO), between 1975 and 2016, the 
prevalence of obesity worldwide tripled, leading to increased obesity-related 
complications such as cardiovascular disease, diabetes and cancer. The Centers for 
Disease Control Prevention (CDC) estimates that the prevalence of obesity in the US 
alone in 2015~2016 was 39.8%, totaling about 93.3 million affected US adults. It is 
widely accepted that the development of obesity-related diseases is, in part, regulated 
by white adipose tissue (WAT), which serves not only as an energy reservoir, but as a 
main secretory organ and site of inflammation. In fact, insulin resistance and metabolic 
syndrome have been directly linked to inflammatory cytokine secretions (1). Cytokines 
are involved in a variety of biological process such as proliferation, differentiation, 
mitochondrial metabolism and insulin resistance (2,3). 
Obesity can be classified into two main categories of hyperplasia (increase in 
adipocyte number) and hypertrophy (increase in adipocyte size) (4). These mechanisms 
contribute to adipose tissue remodeling, which includes alterations in the number and 
size of adipocytes during obesity (5). The resulting hyperplasia occurs through both the 
proliferation of preadipocytes (PAs) and adipocyte differentiation of PAs to mature 
adipocytes (ADs) (6–8). Specifically, mitotic clonal expansion (MCE), which occurs 
during early phases of differentiation, mimics PA hyperplasia by requiring cells to re-
enter cell cycle and go through post-confluent mitosis (4,7). Cell cycle is a tightly 
regulated process with four different phases: Gap 1 (G1), synthesis (S), Gap 2 (G2) and 
mitosis (M), which are each associated with regulatory cyclin proteins (9) (Fig.3.1A). Cell 
cycle progression is highly regulated by cyclin dependent kinases (CDKs) and cyclin-
dependent kinase inhibitors (CKIs) (10). G1 is characterized by cell growth to prepare for 
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DNA replication and requires CDK4 and CDK6 to be coupled with cyclin D1 to promote 
passage through G1 phase by the inactivation of RB by phosphorylation (10,11). This 
inactivation of RB causes the transcription factor, E2F to be released so that it can 
transcribe S-phase genes. Thus, cyclin D1 plays an obligatory role in regulating G1 
progression. This progression is a critical step as once cells enter S phase, they are 
committed to cell division (9,11). Additionally, cyclin D1 has been shown to regulate 
differentiation, independent of cell cycle progression (12,13). As illustrated in Fig.3.1A, 
adipocyte differentiation, or adipogenesis is characterized by sequential increases in 
critical adipogenic proteins such as C/EBPβ, C/EBPδ, C/EBPα, PPARγ, aP2 and ADPN 
(14). Specifically, PPARγ is considered the “master regulator” of adipogenesis and 
requires C/EBPβ for its induction (15–17) (Fig.3.1B). These transcription factors allow for 
the activation of genes that create the phenotype of adipocytes (16).  
Oncostatin M (OSM) is a gp130 or IL-6 type cytokine originally discovered based 
on its antiproliferative activity in a human melanoma cell line (18). Among the various 
biological processes that gp130 cytokines are involved in, these cytokines have recently 
been studied as potential therapeutic targets in obesity as research has shown that 
adipocytes and adipose tissue are sensitive to their secretion. OSM is unique because it 
has it’s own specific receptor that heterodimerizes with gp130 termed OSMRβ (19). 
While OSM is not specifically produced by PAs or ADs, both cell types have OSM 
receptors, allowing them to be responsive to OSM secreted from other cells within the 
adipose tissue such as T-cells and macrophages (20,21). Importantly, both OSM and 
OSMRβ levels are significantly increased during conditions of obesity (22,23). It is well 
accepted that the increases in OSM inhibit adipocyte differentiation (3,21,24–26). 
Additionally, in several cell types, OSM regulates cellular proliferation, as well as cell 
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cycle progression by inhibiting the transition from G1 to S phase and regulating cyclin D1 
protein (19,20,27). Our lab, as well as others, has shown that OSM up-regulates 
hypoxia-inducible factor-1 alpha (HIF-1α) (28). HIF-1α is normally regulated under low 
oxygen conditions, which occurs within the adipose tissue as it expands with obesity 
(29). Like OSM, hypoxia also inhibits differentiation and regulates cell cycle progression 
(30–33). Specifically, hypoxia-mediated inhibition of adipogenesis has been shown to 
involve a direct effect of HIF-1α on PPARγ (34). Collectively, increases in both OSM and 
hypoxia occur during obesity and cause changes in cell growth, differentiation and cell 
cycle progression. However, whether the effects of OSM on differentiation and cell cycle 
are due to HIF-1α is unknown. Hence, this study investigated the effect of OSM on 
adipocyte growth and differentiation and the role of HIF-1α in these changes. 
In this report, we examined the impact of OSM on adipose tissue remodeling by 
examining both PA growth and AD differentiation using 3T3-L1 murine adipocytes. This 
cell line allowed for the examination of both PA proliferation as well as differentiation 
from PAs to mature ADs. This study has determined that OSM inhibits both PA 
proliferation, as well as differentiation. Data reveal that OSM reduces cyclin D1 in both 
subconfluent proliferating PAs and during the proliferative MCE phase of differentiation. 
These data suggest that OSM causes cells to drop out of cell cycle very early. Due to 
previous research that connects OSM with HIF-1α, we sought to determine if there is a 
relationship with HIF-1α and the effect of OSM on cell growth and differentiation. 
Interestingly, knockdown of HIF-1α partially restored the OSM-mediated inhibition of 
cyclin D1 and differentiation markers PPARγ, aP2 and C/EPBα. This demonstrates a 
role for HIF-1α in the effect of OSM on adipogenesis. Collectively, these observations 
suggest that OSM is not only involved in adipose tissue remodeling via impacts on 
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proliferation and differentiation, but that HIF-1α is plays a mechanistic role in this 
process. 
Materials and Methods 
Materials. Modified Eagle’s Medium (DMEM), calf bovine serum (CS) and 
Trypsin-EDTA were purchased from Invitrogen. Murine Oncostatin M (OSM) was 
purchased for Sigma. Antibodies used for immunoblotting include cyclin D1, p-RB, 
ADPN, HIF-1α, HIF-1β, total-ERK and α-tubulin purchased from Cell Signaling, cyclin A, 
cyclin B1, C/EBPβ, PPARγ, aP2, and C/EBPα were purchased from Santa Cruz 
Biotechnology and OSMRβ was purchased from R&D Systems. Dicer-substrate siRNA 
duplexes were purchased from Integrated DNA Technologies. Enhanced 
chemiluminescence (ECL) reagents were obtained from Perkin-Elmer Life Sciences. All 
TaqMan primer probes used in this study were purchased from Applied Biosystems. 
 Cell Culture and Induction of Differentiation. The murine 3T3-L1 cell line was 
purchased from Howard Green, Harvard Medical School. For proliferation studies, cells 
were propagated in DMEM supplemented with 10% CS and experiments were 
conducted in subconfluent proliferating PAs. For differentiation studies growth medium 
was replaced at 2-days post-confluence with DMEM supplemented with 10% FBS, 
0.5mM 1-methyl-3-isobutylxanthine, 1 µM dexamethasone, and 1.7 µM insulin (MDI). 
Throughout the study, ‘time 0’ refers to density-arrested cells immediately before the 
addition of MDI to the culture medium. Throughout the study, ‘d0’ refers to density-
arrested cells immediately prior to MDI stimulation as described in figure legend. 
Experiments described herein were conducted within the period of differentiation 
spanning from density arrest (d0) through 8 days (d8) post-MDI. All experiments were 
repeated at least 3 times to validate results and ensure reliability.  
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 Immunoblotting. Cell monolayers were washed with phosphate-buffer saline 
(PBS) and scraped into ice-cold lysis buffer containing 0.1 M Tris (pH 7.4), 150 mM 
NaCl, 10% sodium dodecyl sulfate (SDS), 1% Triton X, 0.5% Nonidet P-40 (NP40), 1 
mM EDTA, 1 mM EGTA. Phosphatase inhibitor (2 µM sodium orthovanadate) and 
protease inhibitors (0.3 µM aprotinin, 21 µM leupetin, 1 µM pepstatin, 50 µM 
phenanthroline, 0.5 µM phenylmethylsulfonyl fluoride) were added to lysis buffer 
immediately prior to cell harvest. Cell lysates were sonicated and centrifuged (15,000g, 
10 min, 4°C), and the supernatant transferred to a fresh tube. Protein content was 
determined by bicinchoninic acid (BCA) procedures according to manufacturer’s (Pierce, 
Rockford, IL) instructions. Equal amounts of whole cell lysate protein were separated by 
SDS-PAGE electrophoresis. Cell lysates were mixed with loading buffer containing 
0.25M Tris (pH6.8), 4% SDS, 10% glycerol, 0.01% bromophenol blue, and 10% 
dithiothreitol, then heated at 80°C for 5 min prior to electrophoresis. Proteins were 
resolved on SDS-polyacylamide gel electrophoresis (PAGE) and transferred to 
polyvinylidene fluoride (PVDF) membranes (Millipore corp., Billerica, MA). After transfer, 
membranes were blocked with 4% milk and probed with indicated primary antibodies 
overnight at 4°C. Membranes were subsequently probed with horseradish peroxidase 
conjugated secondary antibodies for 2 hrs at room temperature. Membranes were 
immersed in ECL and data visualized by autoradiography using CL-XPosure film 
(Pierce).  
 RT-PCR. Total RNA was extracted and genomic DNA contamination was 
removed using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA), according to 
manufacturer protocol. Total RNA was quantified with a Nanodrop ND-1000 
spectrophotometer. Total RNA was reverse-transcribed to cDNA in a 10 µl reaction 
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volume using a high capacity cDNA reverse transcription kit (Applied Biosystems). The 
reverse transcription (RT) master mix containing RT buffer, deoxyribonucleotide 
triphosphate (dNTP) mix, RT random primers, RNase inhibitor (1.0 U/µl), and MultiScribe 
RT was added to 1 µg RNA and RNase-free water. Reverse transcription reaction 
conditions followed the protocol (25°C for 10 min, 37°C for 120 min, 85°C for 5 sec, 
followed by 4°C in definitely/ RT complete) and utilized the Gene Amp PCR System 
9700 thermal cycler (Applied Biosystems) for cDNA synthesis. PCR amplification was 
run utilizing the 7500 fast system (Applied Biosystems) that consisted of enzyme 
activation at 95°C for 20 sec, followed by 40 cycles of denaturation at 95°C for 3 sec 
combined with annealing /extension at 60°C for 30 sec. All data were analyzed with the 
ABI 7500 real time PCR system. All TaqMan primer probes used in this study were also 
purchased from ABI. Data were recorded and analyzed with ABI Sequence Detector 
Software and graphs visualized with Excel software. All data were presented as mean ± 
standard error of the mean (SEM) and representative of duplicate determinations. Data 
were normalized to 18S and measured as relative differences using the 2-ΔΔCT method 
as previously described (35,36). Statistical analyses were conducted using SPSS. 
Differences in cell number were determined via student’s t-test where a p-value of <0.05 
was considered significant. 
 RNA Interference. Dicer-substrate short interfering RNA (siRNA) for HIF-1α 
specific sequences as well as non-targeting sequences were transfected using 
Lipofectamine RNAiMAX transfection reagent according to manufacturer’s (Invitrogen) 
protocol. Briefly, 3T3-L1 preadipocytes were propagated in 6-well culture dishes until 
reaching confluence. Cells were then stimulated with 9 µl Lipofecatime RNAiMAX 
reagent and either 10 µM HIF-1α specific si RNA or non-targeting siRNA for 48 hr. 
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Growth medium was subsequently switched to differentiation medium containing MDI +/- 
OSM as described above. 
Results 
OSM Inhibits Proliferation. OSM was first discovered for its ability to inhibit 
cancer growth in the A375 human melanoma cell line (37). More recently, research has 
shown that OSM also inhibits osteosarcoma proliferation and reduces breast cancer in 
several cell lines (38,39). However, published reports also suggest that in some cell 
types, OSM induces proliferation and tumor growth (18,40). To investigate the effect of 
OSM on cell growth of proliferating PAs, subconfluent PAs were stimulated with OSM 
and cell count was measured each day by hemocytometer until untreated cells reached 
confluence (d6). As illustrated in Fig.3.2, OSM reduced PA proliferation relative to 
untreated controls. While statistical differences were reached by 2 days post-OSM 
treatment, by day 6, OSM-treated cells were ~50% less confluent that untreated. These 
data suggest that OSM inhibits subconfluent PA proliferation. 
OSM Reduces Cyclins during Proliferation. To determine if OSM inhibits 
proliferation in PAs by mechanisms involving cell cycle, subconfluent PAs were 
stimulated with OSM and whole cell lysates were harvested over time. Lysates were 
immunoblotted for cyclin D1, cyclin A, cyclin B1 and p-RB. First, data reveal that OSM 
caused a considerable reduction in cyclin D1 protein by 24h compared to control. 
Additionally, although changing the media allowed for cell cycle progression, by 72h, 
cells treated with OSM had decreased levels of cyclin A, cyclin B1 and p-RB compared 
to control (Fig.3.3). As cyclin D1 promotes G1 phase progression and phosphorylation of 
RB to allow E2F-mediated S-phase gene transcription, these data suggest that OSM 
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causes cells to exit the cell cycle by a mechanism involving cyclin D1 suppression, which 
is not consistent with a G1/S phase block. 
OSM Affects Cyclin D1 Protein and mRNA. Based on our finding that OSM 
greatly reduces cyclin D1 protein, we determined the effect of OSM on cyclin D1 protein 
and RNA. Subconfluent PAs were left untreated or treated with OSM and whole cell 
lysates and total RNA were collected over time. Cyclin D1 mRNA and protein expression 
was examined via RT-PCR and immunoblot analysis, respectively. As expected, media 
change accelerated cell cycle progression as indicated with increased levels of cyclin D1 
protein and mRNA (Fig.3.4). Additionally, we confirmed our previous findings that OSM 
causes a greater reduction in cyclin D1 protein compared to control (Fig.3.4B). However, 
unlike previous reports by others suggesting that cyclin D1 is reduced by OSM through 
changes in protein stability (27), we found that OSM reduces cyclin D1 mRNA as early 
as 12h post-OSM treatment (Fig.3.4A). These data reveal that OSM causes PAs to drop 
out of the cell cycle very early by affecting levels of both cyclin D1 protein and mRNA.  
OSM Inhibits Differentiation. Just as cell growth and proliferation of PAs are 
important factors in the development of obesity, the process of differentiation from PAs 
to mature ADs involves a cascade of events that cause changes in cell morphology, 
hormone sensitivity and gene expression that are important in the understanding of 
adipocyte cell function and how it relates to obesity (41). Importantly, the inhibition of 
differentiation can block adipose tissue expansion, which is recognized as causing 
insulin resistance (20). Previous research has shown that in some cell types, OSM 
inhibits differentiation (3,20,24–26). In order to confirm that OSM inhibits differentiation in 
our 3T3-L1 cell line, density-arrested PAs were stimulated with or without OSM in the 
presence of differentiation-inducer cocktail, MDI. Cells were harvested over a 6-day time 
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course and lysates were immunoblotted for differentiation markers C/EBPβ, PPARγ and 
ADPN, as well as OSMRβ. As illustrated in Fig.3.5, OSM reduced levels of all three 
differentiation markers. Of note, while OSMRβ was reduced over the course of 
differentiation in untreated cells, OSM caused an increased and sustained induction of 
OSMRβ in the presence of MDI. These data confirm the ability of OSM to inhibit 
adipocyte differentiation. 
OSM Inhibits Differentiation during Clonal Expansion. The first phase of PA 
differentiation involves mitotic clonal expansion (MCE), which is characterized by cells 
synchronously progressing through at least one or more rounds of DNA replication or 
cell cycle during the first two days of differentiation (4). After MCE, cells then acquire the 
characteristics of mature adipocytes including alterations in cell shape and an increase 
in glucose transporters, insulin receptors and adipocyte proteins such as leptin and 
adipsin (4,41). To establish if MCE is a critical period for OSM’s effect on differentiation, 
PAs were stimulated with or without OSM in the presence of MDI. OSM stimulation 
occurred on d0, d2, d4 or d6 and all cell lysates were collected on d8 and immunoblotted 
for differentiation markers PPARγ, aP2, C/EBPα and ADPN. As illustrated in Fig.3.6, 
addition of OSM on d0 and d2 prevented full induction of differentiation, whereas OSM 
beyond this time period had no effect of differentiation. These data suggest that OSM 
inhibits differentiation during clonal expansion. 
OSM Reduces Cyclin D1 during Differentiation in a Dose-Dependent 
Manner. Our previous data suggest that the effect of OSM on proliferation is mediated 
through a reduction in cyclin D1. Because clonal expansion is characterized by 
postconfluent proliferation, we sought to determine if cyclin D1 plays a role in the effect 
of OSM on differentiation. Density-arrested PAs were stimulated with or without varying 
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concentrations of OSM in the presence of MDI and collected within MCE phase at 32 hr. 
Lysates were subjected to immunoblot analysis for cyclin D1. We observed a dose-
dependent effect of OSM on cyclin D1 during MCE (Fig.3.7). These data suggest that 
cyclin D1 may be involved in the OSM inhibition of differentiation.  
Effect of OSM on Differentiation Over Time. Our previous studies have shown 
that OSM induces HIF-1α. Research has shown that hypoxia inhibits differentiation and 
is dependent on HIF-1α (30,42–44). Additionally, in many cell types hypoxia causes cell 
cycle arrest (9,31,33,45,46). To explore the possibility that there is a link between the 
induction of HIF-1α and the reduction in cyclin D1 by OSM as it relates to the blockade 
of differentiation by OSM, we stimulated density-arrested PAs with or without OSM in the 
presence of MDI and collected lysates over the course of 6 days. Whole cell lysates 
were examined via immunoblot analysis for HIF-1α, HIF-1β, C/EBPβ, PPARγ, cyclin D1 
and cyclin A. As expected, during the first 24 hrs, HIF-1α was strongly induced by OSM 
in the presence of MDI while HIF-1β remained constitutively expressed regardless of 
treatment. OSM also led to sustained induction of OSMRβ. OSM treatment in the 
presence of MDI did not inhibit the induction of C/EBPβ, but did accelerate its decay. 
OSM + MDI did however, completely inhibit the induction of C/EBPβ isoform, LAP1 and 
PPARγ. Additionally, while cyclin D1 was initially induced by MDI at 24 hr like HIF-1α, 
OSM caused it to be degraded rapidly (Fig.3.8). Unlike subconfluent PAs, OSM had no 
effect on cyclin A. These data indicate that the induction of HIF-1α by OSM correlates 
with the inhibition of cyclin D1 and differentiation. 
Role for HIF-1α  in the Effect of OSM on Differentiation. We observed that the 
induction of HIF-1α by OSM is concurrent with a reduction in cyclin D1 and the inhibition 
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of differentiation. To confirm a role for HIF-1α in the inhibition of differentiation, PAs were 
transfected with siRNA targeted to HIF-1α or non-targeting control sequences for 48 hr 
prior to stimulation with MDI with or without OSM. Whole cell lysates were harvested at 3 
hr post-OSM, and at 2 days post-MDI + OSM. This experiment was repeated with whole 
cell lysates being collected at 3 hr post-OSM and then at 5 days post-MDI + OSM. HIF-
1α protein was analyzed at 3 hr post-OSM for each separate experiment. Cyclin D1 and 
C/EBPβ protein was analyzed at 2 days post-MDI + OSM and terminal differentiation 
markers PPARγ, aP2 and ADPN were analyzed at 5 days post-MDI + OSM. Firstly, data 
indicate that transfection with siRNA targeted to HIF-1α greatly suppressed the 
accumulation of HIF-1α by OSM compared to cells transfected with non-targeting control 
sequences in both experiments (Fig.3.9A&C). Data demonstrate that knockdown of HIF-
1α partially restored cyclin D1 but had no effect on C/EBPβ on d2 (Fig.3.9B). Moreover, 
suppression of HIF-1α partially restored C/EBPβ, including LAP1, PPARγ, aP2 and 
C/EBPα by OSM at d5 (Fig.3.9D). HIF-1α knockdown did not restore OSM’s effect on 
ADPN. As C/EBPβ is required during MCE for PPARγ expression and our data show that 
it remains unaffected by OSM at d2, this suggests that HIF-1α may affect C/EBPβ 
activity. Collectively, these data indicate that the induction of HIF-1α by OSM plays a 
role in inhibiting differentiation.  
Discussion 
 This report presents evidence demonstrating that cell growth and differentiation 
of adipocytes is regulated by the inflammatory cytokine OSM. First, we demonstrate that 
OSM directly inhibits the growth of proliferating PAs. Second, we show that OSM causes 
a reduction in cyclin D1, cyclin A, cyclin B1, and p-RB in PAs. Importantly, OSM caused 
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a great reduction to cyclin D1 mRNA and protein. Next we demonstrate that OSM 
inhibits differentiation during the clonal expansion phase and this correlates with an 
induction of HIF-1α and reduction of cyclin D1. Lastly, we show that HIF-1α plays a role 
in the OSM-mediated suppression of cyclin D1 during differentiation and regulators of 
adipocyte differentiation. Collectively, these data demonstrate a role for HIF-1α in the 
OSM-mediated inhibition of PA growth and differentiation.  
 Adipose tissue remodeling that is caused by obesity has been shown to be 
closely related to the function of adipose tissue (47). Adipocyte hyperplasia and 
hypertrophy contribute to adipose tissue expansion and cause downstream effects within 
the adipose tissue as a result of remodeling (5). For example, increases in inflammation 
and hypoxia that result from adipose tissue expansion cause a number of 
consequences, such as increased insulin resistance and adipocyte cell death (48). 
Although normal metabolic function relies on a delicate balance between pro-
inflammatory and anti-inflammatory cytokines, obesity causes an increase in pro-
inflammatory cytokine secretion, such as TNF-α, IL-6, IL-β and OSM (49). OSM was 
originally discovered for its ability to inhibit proliferation of a human melanoma cell line 
(37). However, further evidence has since demonstrated that the effect on proliferation is 
cell type dependent and in some cell types, OSM increases proliferation (27,40,50). 
Hyperplasia, or an increase in PA cell number, plays a major role in the development of 
adipose tissue (51,52). Therefore, to gain a better understanding of how PA proliferation 
is regulated during obesity, we addressed the hypothesis that OSM affects PA cell 
growth. Data presented here indicate that OSM dramatically reduces cellular 
proliferation. Others have shown that OSM inhibits proliferation by inhibiting cell cycle 
progression at the G1/S transition (27,53,54). Our data demonstrate that OSM 
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dramatically reduces cyclin D1, cyclin A and cyclin B1, as well as p-RB in proliferating 
PAs. The decline in cyclin D1 in our report indicates that these cells arrest early in G1 as 
opposed to late G1, which would be characterized by elevated cyclin D1, as reported by 
others (53,54). Due to the very pronounced effect of OSM on cyclin D1 and its regulatory 
role in G1 phase progression, we chose to focus on this cyclin in our following studies. 
Others have reported that OSM regulates cyclin D1 in skeletal muscle cells by 
ubiquitin/proteasomal-dependent degradation with no effect on cyclin D1 mRNA (27). 
While it is possible that cyclin D1 is also regulated by a post-transcriptional mechanism, 
data presented here demonstrate that OSM significantly reduces the expression of cyclin 
D1 mRNA indicating an inhibitory effect on transcription. 
 Adipogenesis, or the conversion of PAs to ADs has previously been targeted for 
antiobesity therapeutics. However, mounting evidence suggests that the blockade of 
adipocyte expansion is related to insulin resistance and type 2 diabetes (15). Other 
published reports have indicated that several cytokines such as TNF-α and IL-B, and 
also including OSM inhibit differentiation (24,25). However, the mechanism by which 
OSM inhibits differentiation of adipocytes is yet to be fully elucidated. Data presented in 
this dissertation here establish that OSM inhibits differentiation of adipocytes in the 3T3-
L1 cell line. We demonstrate that OSM completely abrogates the induction of the 
“master regulators” of adipogenesis, PPARγ and C/EBPα. While OSM does not 
completely inhibit the induction of C/EBPβ, it accelerates its decay. Because the 
induction of C/EBPβ during MCE acts as a transcription factor to drive induction of 
PPARγ and C/EBPα (Fig.3.1B) (7,14), the fact that OSM inhibits PPARγ, but not 
C/EBPβ, raises the possibility that OSM may somehow inhibit the activation of C/EBPβ. 
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Along this premise, other reports have demonstrated that OSM does not affect mRNA or 
protein level of C/EBPβ, but does inhibit its activity (25).  
We observed that the inhibitory effects of OSM on differentiation occurred only 
during the first days following hormonal induction kinetically coinciding with mitotic clonal 
expansion and C/EBPβ and preceding the expression of PPARγ and C/EBPα. Once the 
latter two transcriptional regulators were induced, cells became refractory to late stage 
stimulation. We explored the possibility that this refractory period was due to down 
regulation of the OSM receptor β (OSMRβ) as others have shown peak expression 
during the first 24 hrs followed by progressive decline in protein over the remaining 
course of differentiation (22). In refute of this hypothesis, however, we observed that 
continued stimulation with OSM throughout the course of differentiation prevented the 
progressive loss of receptor protein observed in the absence of OSM clearly 
demonstrating that the refractory period during late stages of differentiation was not due 
to down-regulation of the receptor. While the mechanism promoting OSMRβ 
accumulation in the presence of OSM stimulation in adipocytes has yet to be 
determined, these data are consistent with other reports showing that the expression of 
OSMRβ is up-regulated by OSM stimulation in fetal hepatocytes and granulosa cells 
(55,56). Collectively, these data indicate that OSM impinges on differentiation only 
during early phases characterized by C/EBPβ and MCE. 
The early phase of adipocyte differentiation is characterized by several rounds of 
cell cycle during MCE, as well as the induction of a cascade of transcription factors that 
drive terminal differentiation (Fig.3.1) (7,41). Our previous data demonstrated a 
significant effect of OSM on cyclin D1. Cyclin D1 is critical for progression through G1 
phase during MCE by inactivating RB to allow passage through the restriction point for 
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DNA synthesis (57). Evidence also suggests that cyclin D1 directly interacts with 
C/EBPβ during early differentiation in a cyclin dependent kinase manner (13,57). Data 
presented in our report demonstrate that OSM reduces cyclin D1 in a dose-dependent 
manner during MCE. This raises that possibility that the loss of cyclin D1 may be 
involved in the inhibition of differentiation. Further analyses exploring the effect of OSM 
over six consecutive days of differentiation revealed that OSM stimulation suppressed 
cyclin D1 by day 2 of differentiation, with little affect on cyclin A until day 4. These data 
suggest that suppression of cyclin D1 temporality occurred after cells had moved beyond 
the restriction point leading to cyclin A expression and S phase progression. Our data 
indicate that OSM causes an early decay of cyclin D1 and inhibits the induction of the 
“master regulator” of adipogenesis, PPARγ. It is widely accepted that MCE, which 
includes the early induction of cyclin D1, is required for terminal differentiation (7). This 
suggests that there is a critical level and timing of cyclin D1 induction needed for 
differentiation.  
Our unpublished data and others (28) demonstrate that OSM can regulate HIF-1α 
in normoxic conditions. Consistently, data presented here indicate that OSM induces 
HIF-1α during early phases of differentiation concurrently with the induction of cyclin D1 
and C/EBPβ. This raises the possibility that OSM may regulate cyclin D1 through HIF-1α 
and affect differentiation through a cell cycle independent mechanism. It is well 
established that for HIF-1α to act as a functional transcription factor, it must 
heterodimerize with HIF-1β (58,59). Our data suggest that HIF-1α is functional during 
MCE upon the stimulation with OSM due to the constitutively expressed HIF-1β. A 
published report found that OSMRβ-deficient mice had increased insulin resistance (60). 
Our data demonstrated OSM led to sustained OSMRβ in the presence of MDI and to the 
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inhibition of differentiation. Given that the blockade of adipogenesis increases insulin 
resistance, our data would suggest that OSMRβ does not protect against insulin 
resistance. 
 Previous research indicates that hypoxia inhibits adipocyte differentiation and 
that HIF-1α is involved in this inhibition (30,43,61). As our data has shown that OSM 
induces HIF-1α and that OSM inhibits differentiation, it is conceivable that HIF-1α plays 
a role in the OSM-mediated blockade of adipogenesis. Data in this investigation 
demonstrate that the effect of OSM in late stages (d5) of differentiation on C/EBPβ, 
PPARγ, aP2 and C/EBPα is rescued by HIF-1α knockdown. However, HIF-1α 
knockdown did not rescue the effect of OSM on ADPN inhibition. These data confirm a 
partial role for HIF-1α in OSM-mediated inhibition of differentiation. As OSM is a 
pleiotropic cytokine affecting a variety of genes and processes and we would not expect 
the inhibition of differentiation by OSM to be solely regulated through HIF-1α. Moreover, 
examination of the effect of HIF-1α knockdown in the presence of OSM during MCE on 
d2 of differentiation suggests that HIF-1α is involved in the regulation of cyclin D1 by 
OSM. OSM, regardless of HIF-1α, had no effect on the induction of C/EBPβ during 
MCE. This is consistent with literature that suggests hypoxia has minimal effect on 
C/EBPβ (30). However, this finding is surprising since C/EBPβ binds directly to the 
promoter regions of C/EBPα and PPARγ to induce their expression (17). This is 
consistent, however, with other research indicating that OSM does not affect the 
expression of C/EBPβ (25). This raises the possibility that C/EBPβ in the presence of 
OSM may not be functional. Several studies have proposed that C/EBPβ is auto-
inhibited and must be derepressed for functionality (62,63). As mentioned earlier, some 
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research demonstrates the interaction between cyclin D1 and C/EBPβ for terminal 
differentiation (13). This raises the possibility that there was enough cyclin D1 present in 
early MCE to activate cyclin A for cell cycle progression but not enough to activate 
C/EBPβ for terminal differentiation. Collectively, our data demonstrate an essential role 
for HIF-1α in the OSM-mediated inhibition of differentiation, although the mechanisms by 
which this occurs remains unresolved. 
In summary, data presented in this report demonstrate that OSM affects adipose 
tissue remodeling by impacting cellular proliferation and adipocyte differentiation. Our 
data provide evidence that OSM inhibits adipogenesis specifically during early phases of 
differentiation, which includes MCE. Our data also indicate that OSM significantly 
reduces cyclin D1 in both subconfluent proliferating PAs and during adipogenesis. While 
the reduction of cyclin D1 in proliferating PAs likely affected cell growth by a mechanism 
related to cell cycle, our data suggest that the effect of OSM on cyclin D1 during MCE 
likely inhibited differentiation by a cell cycle independent mechanism. We also report that 
the loss of HIF-1α partially restored cyclin D1 and differentiation by restoration of 
adipogenic factors such as PPARγ and C/EBPα.  Although further studies are needed to 
elucidate the regulatory mechanism by which OSM-mediated HIF-1α induction inhibits 
differentiation, this study establishes a platform for future investigations, especially in 
regards to the relationship between cyclin D1 and C/EBPβ. As studies continue to 
examine the regulation of cell growth and differentiation by OSM and HIF-1α, insights 
into these mechanisms will provide greater understanding as to how inflammation and 
hypoxia lead to adipose tissue remodeling. 
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Figure 3.1. Characterization of Regulatory Factors during Adipose Tissue 
Hyperplasia. A) During subconfluent asynchronous proliferation, cells are constantly 
undergoing cell cycle and express varying levels cyclin D1, cyclin A, cyclin B, C/EBPβ 
and C/EBPδ. Upon stimulation with MDI at 2d post-confluence, cells undergo 
synchronous cell cycle during MCE, in which cyclin D1 is induced first and drives 
subsequent increases in cyclin A and cyclin B. MCE is also characterized by increases 
in C/EBPβ and C/EBPδ, which are obligatory for downstream targets such as C/EBPα 
and PPARγ, which lead to the phenotype of mature adipocytes. B) During MCE, 
C/EBPβ’s auto-inhibition is repressed, allowing for the induction of PPARγ and C/EBPα, 





Figure 3.2. OSM Inhibits Proliferation. Proliferating preadipocytes were stimulated 
with 1nM OSM. Cell count was measured every day until control cells reached 
confluence (d6). Statistical significance was determined by Student’s t-test (*p<0.05).  
 
 
Figure 3.3. OSM Reduces Cyclins during Proliferation. Proliferating preadipocytes 
were stimulated with 1nM OSM and cell lysates were harvested over time. Protein 








Figure 3.4 OSM Affects Cyclin D1 Protein and mRNA. Proliferating preadipocytes 
were stimulated with 1nM OSM. A) Total RNA was collected and gene expression of 
cyclin D1 was measured via qRT-PCR. All data were normalized to 18S rRNA and 
expressed relative to untreated cells (0h). Statistical significance was determined by 
Student’s t-test (*p<0.05). B) Cell lysates were collected over time and protein 












Figure 3.5 OSM Inhibits Differentiation. Preadipocytes were stimulated to differentiate 
with the hormonal cocktail MDI as outlined above and with 1 nM OSM. Cell lysates were 
collected over a 6-day time course and protein expression of C/EBPβ, PPARγ, ADPN, 
























Figure 3.6. OSM Inhibits Differentiation during Clonal Expansion. Preadipocytes 
were stimulated to differentiation with MDI and stimulation of 1 nM OSM occurred every 
2 days for 6 days. A) Cell lysates were all collected on d8 prior to immunoblot analysis of 
PPARγ, aP2, C/EBPα, ADPN and total-ERK. B) Examination of cell morphology of 
untreated preadipocytes or treated with OSM. Cells were assessed for lipid 
accumulation using phase contrast microscopy. 
OSM d0 OSM d2 





Figure 3.7. OSM Reduces Cyclin D1 during Differentiation in a Dose-Dependent 
Manner. Preadipocytes were stimulated to differentiate with MDI concurrent with varying 
concentrations of OSM stimulation. Cell lysates were collected at 32h post-MDI and 
analyzed for protein expression of cyclin D1 and total-ERK by immunoblotting.  
 
 
Figure 3.8. Effect of OSM on Differentiation Over Time. Preadipocytes were 
stimulated to differentiate with MDI in the presence or absence of 1nM OSM. Cell lysates 
were collected over a 6-day time course prior to immunoblot analysis for HIF-1α, HIF-1β, 






Figure 3.9. Role for HIF-1α  in the Effect of OSM on Differentiation. Preadipocytes 
were transfected with Lipofectamine RNAiMAX reagent in the presence of non-targeting 
control siRNA or siRNA for HIF-1α for 48h prior to stimulation with MDI or MDI + OSM. 
A) Cell cell lysates were collected at 3h post-OSM prior to immunoblot analysis for HIF-
1α and total-ERK. B) Cell lysates were collected at 2d post-MDI +/- OSM prior to 
immunoblot analysis for cyclin D1, C/EBPβ and total-ERK. C) Cell lysates were collected 
at 3h post-OSM prior to immunoblot analysis for HIF-1α and total-ERK. D) Cell lysates 
were collected at 5d post-MDI +/- OSM prior to immunoblot analysis for C/EBPβ, PPARγ, 








Figure 3.10. Proposed Working Model for Role of HIF-1α  in OSM-Mediated Effects 
on Preadipocyte Proliferation and Differentiation. A) OSM increases HIF-1α, which 
causes a reduction in cyclin D1 to inhibit subconfluent proliferation in preadipocytes. B) 
Differentiation cocktail MDI normally induces synchronous proliferation during MCE 
where cyclin D1 drives cell cycle by cdk4-dependent mechanism (left). When OSM is 
present during MDI stimulation, the induction of HIF-1α causes cyclin D1 to decay and 
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Data presented in this dissertation represent evidence demonstrating the 
regulation of hypoxia inducible factor-1α (HIF-1α) by Oncostatin M (OSM) during 
normoxia and specific downstream adaptations in 3T3-L1 adipocytes. Findings 
presented in Ch.2 collectively demonstrated that OSM, through several well-known 
signaling pathways, transcriptionally regulates HIF-1α and leads to metabolic 
adaptations during normoxic conditions. Data from Ch.3 demonstrated that (OSM) 
regulates adipose tissue remodeling by reducing cellular growth and differentiation and 
that these effects are, in part, mediated by HIF-1α. Collectively, data presented in this 
dissertation provide evidence for the regulation of HIF-1α by OSM during normoxia and 
the overall adaptations made by adipocytes in response to OSM-mediated HIF-1α 
induction, linking hypoxia and inflammation during obesity. While data from this 
dissertation established a role for HIF-1α in the effect of OSM on adipocytes, questions 
for future investigation have been generated. This chapter will discuss findings from 
previous chapters and focus on potential areas of research. 
Data presented in Ch.2 demonstrated that inflammatory cytokine OSM induces 
HIF-1α in preadipocytes (PAs) under normoxic conditions. We also found that TNF-α 
induced HIF-1α (data not shown), but the induction was weak in comparison. Our 
preliminary findings demonstrated that HIF-1α induction by OSM was as great as the 
induction by CoCl2, a well-known hypoxia mimetic. However, it differed in its kinetics and
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mechanisms, with OSM-mediated regulation being dependent on transcription. However, 
examining which sequences and regions of the HIF-1α promoter are required for OSM to 
induce HIF-1α transcription would give a more detailed insight into regulatory 
mechanisms. Preliminary findings from our lab and others have demonstrated that OSM 
activates a variety of signaling pathways that link OSM to its downstream effects (1–4). 
While this dissertation was limited to signaling pathway inhibitors to examine their role in 
OSM-mediated HIF-1α induction, studies involving knockdown of signaling pathways to 
examine mRNA and protein induction is critical for understanding which pathways link 
OSM to HIF-1α transcription. Although our preliminary studies examined only STAT3, 
ERK and AKT signaling pathways, other pathways have been shown to respond to 
OSM, such as STAT5 (4). 
In order to act as a transcription factor, it is a requirement for HIF-1α to 
translocate to the nucleus and heterodimerize with HIF-1β (5,6). HIF-1α can then bind 
the core consensus sequence within the hypoxia responsive element (HRE) of HIF-1α 
target genes (5). While our studies did find that OSM-induced HIF-1α was bound to HIF-
1β for functionality, our research did not investigate which signaling pathways activated 
by OSM increased HRE activity. An interesting addition to the story would be to 
knockdown several of the signaling pathways in the presence of OSM and examine the 
HRE promoter activity. These data would further confirm the role of critical signaling 
pathways that link OSM to the downstream HIF-1α mediated effects.  
It is well known that hypoxia regulates many different genes encoding for a 
variety of biological processes, such as cellular proliferation, angiogenesis, inflammation 
and glycolysis (7,8). Our data confirmed that OSM regulates genes involved in the same 
processes as hypoxia and did so through mechanisms involving HIF-1α. Our data 
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demonstrated that glycolytic genes as well as genes associated with angiogenesis were 
up-regulated by OSM in a HIF-1α-dependent manner. However, investigations 
examining the effect of OSM on the promoter regions of these genes, as well as gene 
promoter constructs mutated at the HRE, would increase our understanding of precise 
mechanisms by which OSM regulates these genes. We also found a role for HIF-1α in 
OSM-mediated increases in glucose uptake and lactate production, which supports an 
increase in glycolytic function. Seahorse biotechnology allows researchers to measure 
oxygen consumption rate and extracellular acidification rate of cells in real time. 
Although we attempted to measure glycolytic function of adipocytes in response to OSM, 
using the Seahorse, the variability of this technology made it difficult to determine the 
true bioenergetics. However, future investigations to optimize conditions for these cells 
and determine a role for both OSM and HIF-1α in adipocyte bioenergetics would likely 
support a shift in metabolism toward glycolytic flux.  
Our data further support a role for HIF-1α in OSM-mediated metabolic adaptation 
through the observation that the angiogenic factors, VEGF and PAI-1 were increased. 
However, exploring the secretion of VEGF and PAI-1 by adipocytes in response to OSM 
and HIF-1α would further confirm a role for vascularization. Published reports have 
demonstrated that hypoxia increases the production of a conglomeration of adipokines 
such as leptin, fasting induced adipose factor (FIAF), interleukin-6 (IL-6), macrophage 
migration inhibitory factor (MIF) and others (9–13). Other reports show evidence of the 
effect of OSM on adipokine induction such as tissue inhibitor metalloproteinases 1 
(TIMP1) and insulin-like growth factor-binding protein 3 (IGFBP3) (14). Future 
investigations of the role of HIF-1α in the effect of OSM on adipokines known to be 
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associated with hypoxia, including those unrelated to angiogenesis, would provide 
additional evidence for the link between inflammation and hypoxia found during obesity. 
Observations presented above highlight our preliminary data and future studies 
involving the regulation of HIF-1α by OSM and the role of this relationship in metabolic 
adaptation, such as glycolysis and vascularization. In this dissertation we have also 
identified a role for HIF-1α in the regulation of adipose tissue remodeling by OSM (Ch.3). 
While our preliminary studies revealed that OSM inhibited subconfluent PA proliferation, 
we mostly focused on the reduction of cyclin D1 as the mechanism of inhibition of cell 
growth. However, studies analyzing cell cycle with flow cytometry would contribute 
greatly to our understanding of how OSM regulates cell cycle progression in proliferating 
PAs. Additionally, our preliminary data demonstrated that OSM induces HIF-1α. 
Research in cancer cells reveals that HIF-1α suppresses cyclin D1 to inhibit proliferation 
(15). An interesting addition to our story would be to suppress HIF-1α in subconfluent 
proliferating PAs and examine cyclin D1, as well as cell cycle. 
Furthermore, we showed that OSM inhibits adipocyte differentiation. It’s generally 
accepted that inhibition of adipogenesis is associated with reduced insulin sensitivity 
(16). In this sense, these data further the link between inflammation and adipocyte 
dysfunction. An important addition to our data would be to examine the effect of OSM 
overexpression on PPARγ in adipose tissue isolated from mice.  These data would give 
insight into the effects of OSM on adipogenesis in vivo. We revealed that mitotic clonal 
expansion (MCE) was a critical period for OSM to inhibit differentiation. Addition of OSM 
after MCE had no effect on the conversion of PAs to adipocytes (ADs). It was a plausible 
hypothesis that this was due to the loss of OSMRβ over the course of differentiation that 
our lab and others (4) have seen. However, our data show that the addition of OSM 
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sustained OSMRβ during differentiation, thereby disproving the hypothesis that the loss 
of OSMRβ was responsible for the effect of OSM being confined to MCE. In fact, an 
experiment we performed addressing the effect of MDI components on OSMRβ and 
PPARγ in late stages of differentiation showed an inverse relationship where PPARγ was 
expressed the most when OSMRβ was the lowest.  
It’s been previously document in a published report that there is an association 
between cyclin D1 and the C/EBP’s (17). Recent evidence revealed that cyclin D1 binds 
to LAP1, the most predominant isoform of C/EBPβ to drive expression of PPARγ for 
terminal differentiation (18). Our data demonstrated that OSM reduced both cyclin D1 
and C/EBPβ and completely inhibited the induction of LAP1 over the course of 
differentiation. An important experiment to do would be to examine the interaction of 
cyclin D1 and LAP1 during early differentiation. If cyclin D1 binds to LAP1 and this 
activates C/EBPβ transcriptional function, this could help explain why OSM inhibits 
PPARγ. While we found that LAP1 was inhibited by OSM, we demonstrated that the 
induction of LAP2, which is also a driver of differentiation, was not inhibited. These data 
suggest that the inhibition of differentiation by OSM could occur by inhibiting protein 
expression of LAP1 or inhibiting the function of C/EBPβ. Others have shown that the 
ratio of C/EBPβ isoforms, LAP and LIP, is an important determinant of the fate of 
differentiation (19). However, we found that regardless of OSM stimulation, the 
abundance of LIP was never greater than LAP, which rules out the possibility that OSM 
affects PPARγ by increasing LIP.  
Our preliminary data revealed that the loss of HIF-1α prevented the OSM-
mediated inhibition of differentiation by restoring PPARγ, aP2 and C/EBPα. Other 
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research has shown that HIF-1α regulates PPARγ through the regulation of DEC1, 
which contains functional HREs (20,21). Future examination of the regulation of OSM-
induced HIF-1α on DEC1 could provide another link between OSM and the blockade of 
adipogenesis. Another interesting study to perform would be to examine the effect of 
overexpression of OSM on PPARγ in adipose tissue from HIF-1α deficient mice. This 
would help clarify a role for HIF-1α in OSM-mediated inhibition of adipogenesis in vivo. 
Additionally, we found that HIF-1α suppression partially restored the reduction of cyclin 
D1 by OSM. While our data showed that OSM accelerated the decay of C/EBPβ over 
time and completely inhibited LAP1 induction, the loss of HIF-1α partially restored 
C/EBPβ, as well as LAP1 at d5. Future studies are needed to confirm the relationship 
between cyclin D1 and C/EBPβ, as well as a functional role for C/EBPβ during late 
stages of differentiation.  
During obesity, adipose tissue undergoes the remodeling process to compensate 
for its expansion (22). While our studies were limited to the effects of OSM in vitro on 
proliferation and differentiation, it would be important for future studies to explore the 
effect of OSM in vivo on other aspects of adipose tissue remodeling, such as alterations 
in the extracellular matrix (ECM), fibrosis and macrophage infiltration. Collectively, 
obesity results in adipose tissue dysfunction, which includes impairments in lipid 
metabolism, autophagy, decreased blood flow, macrophage infiltration and increased 
pro-inflammatory cytokine secretion (23). Our preliminary studies found that a cytokine 
(OSM) has the ability to up-regulate a protein named after its induction during hypoxia 
(HIF-1α). While we found that the addition of OSM and CoCl2  synergistically regulated 
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HIF-1α, investigations exploring the downstream effects of the combination may be more 
representative of the magnitude of adaptations that occur during obesity. 
In conclusion, our previous chapters have significantly contributed to the 
knowledge regarding regulation and function of HIF-1α by OSM during normoxia in both 
PAs and differentiating ADs. Data in this dissertation have led to ample questions for 
future studies, especially related to the mechanisms by which OSM affects adipose 
tissue remodeling. Continued research examining the relationship between OSM and 
HIF-1α will lead to a more comprehensive understanding of how inflammation and 
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